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1 Introduction 
The adaptive immune system must ensure the homeostasis of its cell populations to avoid 
lymphoproliferation and exaggerated immune responses in order to prevent immune-
dysregulatory disease. One way to guarantee adaptive immune cell homeostasis is to 
regulate and initiate adaptive immune cell death in the presence or absence of infection1,2. 
1.1 Regulated cell death in T-cells 
The efficacy of the adaptive immune system, and of T-lymphocytes in particular, is based on 
a rapid clonal expansion of pathogen-specific T-cells. To ensure stable absolute T-cell 
numbers following clearance of an infection, controlled T-cell contraction has to occur via 
regulated cell death (RCD). 
RCD is defined as an instantaneous and severe diminution of cells that are exposed to 
physical or biochemical stress factors3,4. RCD has been intensively investigated over the last 
decades. RCD maintains cellular homeostasis by eliminating useless, hyperactive and 
potentially dangerous or infected cells5–8. Also, RCD is of central importance for the 
maintenance of self-tolerance during the development of T-cells in the thymus by negative 
selection9–11. Furthermore, RCD enables dying cells to release intracellular molecules, so 
called damage associated molecular patterns (DAMPs) or alarmins, that can be sensed by 
surrounding cells in a paracrine manner12–15. 
Since cell death is associated with various morphological cellular changes, subtypes of RCD 
have been classified according to the morphological phenotypes. These are (1) type I cell 
death (apoptosis), (2) type II cell death (autophagy) and (3) type III cell death (necrosis)16,17. 
Recent research in RCD led to a new model of classifying these cell death cascades by the 
Nomenclature Committee on Cell Death (NCCD), that focuses on the signaling cascades, 
that are involved and responsible for initiation and execution of RCD. This new classification 
aims to achieve more accuracy by characterizing cell death according to genetic, 
biochemical, pharmacological and functional nature3,17–21. 
1.1.1 Re-stimulation induced vs. cytokine withdrawal induced RCD 
in T-cells 
T-cell contraction following clonal expansion is controlled by two distinct forms of RCD22. An 
optimal T-cell expansion is achieved via a prolonged engagement of an antigen in context 
with the MHC complex on the antigen presenting cell (APC) via the highly specific T-cell 
receptor (TCR). In addition, co-stimulatory molecules such as CD28 are required to support 
optimal T-cell activation. T-cell expansion also requires rapid production of IL-2 and 
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expression of its respective surface receptor (CD25)23. Re-encountering of the cognate 
peptide by an activated antigen-specific T-cell may initiate T-cell apoptosis called re-
stimulation induced cell death (RICD) or activation induced T-cell death (AICD)24,25. 
It is still not entirely clear, why the TCR ligation by pathogen-derived peptide may primarily 
promote survival and proliferation but may induce apoptosis upon subsequent TCR 
ligation26,27. However, it is commonly accepted, that RICD reflects an important and sensitive 
feedback threshold to effectively constrain an effector T-cell pool, depending on quantity and 
quality of the abundant antigen, the amount of growth factors and the cellular 
microenvironment23. During an adaptive immune response, abundance of antigen and levels 
of survival-associated cytokines, such as IL-2, IL-15 and IL-7, decrease following pathogen 
clearance. This withdrawal of cytokines per se may also induce cytokine withdrawal induced 
T-cell death (CWID)28,29. 
Both mechanisms (RICD and CWID) occur at different timepoints during the immune 
response and show different apoptosis kinetics in vitro.  
1.1.2 Extrinsic vs. intrinsic T-cell apoptosis 
T-cell RCD occurs via two signaling pathways that are not mutual exclusive23,30. 
Mitochondrial dysfunction induced by mitochondrial outer membrane permeabilization 
(MOMP) is the orchestrator of intrinsic apoptosis31,32. BAX, BAK and BOK are the only 
apoptosis regulator family (BCL-2) related proteins known so far that induce pores in the 
outer mitochondrial membrane33–36. BAX and BAK are inactive in physiological conditions but 
may be activated to induce MOMP by binding to pro-apoptotic proteins of the BCL-2 family37–
39. These comprise the proteins NOXA and PUMA whose expression is mainly regulated by 
transcriptional activation, while BID expression is regulated post-translationally40–45. Negative 
regulators of BAX and BAK are the anti-apoptotic members of the BCL-2 family, comprising 
BCL-XL, BCL-W and BFL-1. They mediate their apoptosis-inhibiting function by directly 
binding to the pro-apoptotic BCL-2 family members46–48. During intrinsic apoptosis, MOMP is 
followed by cytochrome C release from mitochondria into the cytoplasm where it binds to 
apoptosis peptidase activating factor 1 (APAF1) and pro-caspase 949. This protein complex 
catalyzes the activation of the intrinsic initiator caspase 950. Activated, proteolytically 
processed caspase 9 then catalyzes the proteolytic activation of the effector caspase 3 and 
caspase 7 that are responsible for the morphological and biochemical correlates of 
apoptosis, such as DNA fragmentation, phosphatidylserine exposure and the formation of 
apoptotic bodies due to membrane reorganization18. Another factor that is released from 
mitochondria during MOMP is DIABLO, also known as second mitochondrial activator of 
caspases (SMAC)51–53. Upon release into the cytoplasm, SMAC binds to members of the 
inhibitor of apoptosis proteins including XIAP (x-linked inhibitor of apoptosis) and inactivates 
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its anti-apoptotic function. XIAP stably binds to effector caspases and inhibits their proteolytic 
activation54–56. 
The extrinsic apoptosis pathway is activated by perturbations of the extracellular 
microenvironment. Extrinsic apoptosis is induced by binding of ligands to several death 
receptors on the cell surface. Death receptors comprise FAS (CD95), TNFa receptor 1 
(TNFR1) and TRAIL receptors 1 and 2 (DR4 and DR5)57. Ligation of death receptors lead to 
intracellular conformational changes allowing formation of death-inducing signaling 
complexes (DISC). DISC bind and activate the extrinsic initiator caspases, caspase 8 and 
caspase 10. Processed caspase 8 subsequently activates the execution caspases caspase 3 
and caspase 7. In peripheral mature T-lymphocytes, extrinsic caspase 8 driven apoptosis 
cannot be inhibited by transgenic overexpression of anti-apoptotic BCL-2 proteins58. 
1.1.3 Dysregulated T-cell apoptosis in human disease 
Primary immunodeficiencies (PID) are genetically determined diseases of the immune 
system. PID may develop due to mutations of proteins involved in T-cell apoptosis, thereby 
causing a dysregulation of the immunological homeostasis27,59–63. Abnormal increase of 
apoptosis may cause immunodeficiency, whereas a failure of inducing RCD in immune cells 
can cause autoimmunity or non-malignant or malignant lymphoproliferation. 
Loss of function mutations in the genes encoding for FAS or FASL cause autoimmune 
lymphoproliferative syndrome (ALPS). These patients suffer from non-malignant 
lymphoproliferation (lymphadenopathy, splenomegaly) and autoimmune cytopenia 
(autoimmune hemolytic anemia, immune thrombocytopenia, autoimmune neutropenia, often 
in combination). In vitro assessment of extrinsic, FAS-mediated apoptosis in T- cells of these 
patients reveals impaired apoptosis induction64,65. Mutations in the SH2DA1 gene encoding 
for SAP have been identified to cause X-linked lymphoproliferative disease (XLP), another 
PID that leads to chronic non-malignant lymphoproliferation and a rather specific failure to 
control Epstein-Barr Virus (EBV). SAP deficiency seems to primarily affect T-cell RICD via 
complex mechanisms66–68. A clinically similar disease is observed in patients with loss of 
function mutations in XIAP. Besides lymphoproliferation and failure to control EBV, XIAP 
deficiency is frequently associated with severe and early onset inflammatory bowel disease. 
Also less rare, polygenic diseases are associated with dysregulated apoptosis and 
subsequent polyclonal lymphoproliferation. Such diseases include systemic autoimmune 
diseases such as rheumatoid arthritis (RA), sjögrenʼs syndrome (SS) or systemic lupus 
erythematosus (SLE)69–71. Similarly, chronic virus infections such as infections with HIV or 
EBV are associated with lymphoproliferation caused by virus-mediated apoptotic evasion 
processes61,72,73. 
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These clinical diseases exemplarily demonstrate that small molecule compounds that 
interfere with T-cell apoptosis processes have a high therapeutic potential in the treatment of 
immunological disorders. 
1.2 Nur77, a nuclear orphan receptor 
Many central cellular signaling pathways and key mediators have been investigated for their 
contribution to RCD. Important transcription factors that control RCD are NF𝜅B74 and p5375 . 
The nuclear receptor superfamily contains at least over 60 nuclear transcription factors that 
regulate specific set of target genes76. Those, whose functional ligands have not been 
identified yet, are named nuclear orphan receptors77. A nuclear orphan receptor subfamily is 
the nuclear orphan retinoid receptor family NR4A (nuclear receptor subfamily 4, group A) 
with its members Nur77, Nurr1 and Nor178–80. NR4A family members participate in important 
biological processes such as T-cell development81,82, inflammatory responses83, steroid 
hormone synthesis84 and hepatic glucose metabolism85. Their association with cancer- and 
T-cell apoptosis is of particular interest82,86,87. 
1.2.1 Structure and functional domains of Nur77 
Like most other nuclear receptors, the NR4A members share common functional structures 
such as a N-terminal region that contains a ligand-independent activation function-1 
transactivation domain (AF-1TAD), a very conserved DNA binding domain (DBD), a hinge 
region and a ligand binding domain (LBD) in the C-terminus that contains a ligand-dependent 
AF-2TAD77,88,89. The N-terminal region functions as an adapter region to interact with other 
transcription factors88. The central DBD targets specific DNA structures, so called NGFI-B 
response- and Nur-responsive elements90,91. The LBD is in general responsible for binding 
small lipophilic molecules as ligands to induce specific cellular responses. Also, it contains 
heptad repeats of hydrophobic amino acids involved in nuclear receptor dimerization and 
may also be involved in targeting the right nuclear localization88. There seems to be a 
functional redundancy of Nur77 and other NR4A members, since the biochemical structure 
shows similarities. Some endogenous Nur77 ligands have been proposed in the recent 
years, such as stress signals and growth factors80. But most importantly, chemical 
compounds like Cytosporone-B (Csn-B, isolated from Dothiorella sp. HTF3, an endophytic 
fungus)92,93 or synthesized derivates have been described as effective Nur77 ligands that 
induce Nur77-dependent cellular processes by binding to the Nur77 LBD94–96. 
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1.2.2 Dual role of Nur77 in apoptosis 
Due to its multifunctional binding sites, Nur77 acts as a connection mediator between 
different signaling pathways. With its ability to bind intracellular ligands, other transcription 
factors and its DNA binding motives, Nur77 shows optimal characteristics to regulate the 
cellular homeostatic balance. 
A large number of studies implicate, that Nur77 induces apoptosis in various cancer cell lines 
with a high degree of complexity regarding the involved signal transduction97,98. Nur77 has 
been demonstrated to drive apoptosis in cultured cancer cell lines and in tumors in vivo, 
including melanomas63,94,99–101, lymphomas102,103, leukemia104–107, lung cancer108,109, prostatic 
cancer109–112, breast cancer107,113–115, ovarian cancer116, colon cancer117 and gastric 
cancer114,118,119. In some cancer types, Nur77 expression was even demonstrated to be 
predictive of poor prognosis, since reduced expression could be experimentally correlated to 
poorer overall survival120. 
Conversely, Nur77 has been identified to drive survival and support growth of certain cancer 
cell types121–125. Overall, these studies imply an essential and dual role of Nur77 in driving 
apoptosis vs. survival in cancer cells and tumors that depends on Nur77 cellular localization, 
expression126 and accessability127,128.  
The signaling cascades, that are mainly involved by Nur77 associated apoptosis comprise 
intrinsic30,129–131 and extrinsic30,57 apoptosis. Nur77 driven intrinsic and extrinsic apoptosis 
pathways were mainly activated by MAPK (MEK, ERK1, ERK2, JNK and p38)115,132–136 as 
well as the PI3K/AKT87,137–140 signaling cascades.  
Nur77 has been demonstrated to control expression of pro-apoptotic genes such as FASL or 
TRAIL141,142. In addition, Nur77, upon phosphorylation, has been shown to translocate from 
the nucleus to the cytoplasm where it interacts and inactivates anti-apoptotic Bcl-2 family 
members143. 
1.2.3 Role of Nur77 in T-cell apoptosis 
In T-cells, Nur77 was originally described as an immediate-early induced gene144 following in 
vitro activation of T-cells and subsequently as a gene induced by TCR engagement in T-cell 
hybridomas and thymocytes82,145. 
A dominant negative form of Nur77 impaired TCR-ligation mediated apoptosis (negative 
selection) upon overexpression in thymocytes146–148. 
Some studies reveal, that Nur77 phosphorylation impacts on its pro-apoptotic function, by 
inducing subcellular re-localization to the cytoplasm, specifically to the mitochondria 87,149,150. 
Whether and how the translocation of Nur77 from the nucleus to the cytoplasm occurs in T-
cells remains unclear. Transgenic overexpression of Bcl-2 in T-cells could not block Nur77 
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induced apoptosis144. The requirement of a correct TCR signaling with a proper co-
stimulation or phorbol-ester stimulation for an immediate-early induction of Nur77 expression 
has been repeatedly demonstrated86,151,152. T-cells derived from immunodeficient patients 
with a genetically determined defect in calcium influx could not upregulate Nur77 following 
TCR stimulation compared to T-cells derived from healthy individuals153. 
Since the expression kinetics of Nor1 (NR4A3) following T-cell activation is comparable to 
Nur77 (NR4A1) and the structural homology of their LBD is approximately 90% (N- and C-
terminus is divergent), a shared compensation and certain functional redundancy is very 
likely154. Functional redundancy between Nur77 and Nor-1 might also explain why a targeted 
gene knockout of Nr4a1 (Nur77) did not show an obvious T-cell phenotype in mice81,154. The 
role of Nur77 in re-activation induced apoptosis of mature T-cells has to our knowledge not 
been experimentally addressed yet. 
1.2.4 Modulating Nur77 driven apoptosis via small molecules 
Nuclear receptors represent promising targets for medical compounds to treat cancer and 
metabolic diseases97,155–158. To date, no physiological ligand has been identified yet to bind 
the LBD of Nur77. A variety of small molecules have been used to induce Nur77-dependent 
apoptosis in different cell lines. These include 9-cis-retinoic acid and 1-di (3-indolyl)-1-(4-X-
phenyl) methane92,121, etoposide159, 5,8 diacetoxyl-6-(1-acetoxy-4-methyl-3-pentenyl)-1,4-
naphthaquinones160 and 12 O-tetradecanoylphorbol-13-acetate111,161. Many of these studies 
proposed apoptosis induction via ligand induced heterodimerization of Nur77 with other 
retinoid receptors like retinoid x receptor (RXR) and subsequent translocation to the 
mitochondria. 
1.2.5 Direct Targeting of Nur77 LBD by small molecules 
The oktaketide cytosporone-B (Csn-B), isolated from Dothiorella sp. HTF3, an endophytic 
fungus, has been identified as a direct agonist of Nur77, binding to the Nur77 LBD and 
driving apoptosis by augmentation of the Nur77 transcriptional activity93. This resulted in 
reduced growth of gastric tumors and increased gluconeogenesis in the liver109. These 
cytosporone-B induced phenotypes were shown to depend on Nur77 expression as they 
were absent in Nr4a1 (Nur77) knockout mice93. Apparently, Nor-1 (Nr4a3) was either not 
expressed or could not compensate for Nur77 in this model. More recent studies examined 
cytosporone-B derivate molecules, that contain the biochemical backbone of cytosporone-B, 
but were modified in specific residues to achieve more selective effects regarding apoptosis 
induction or glucose metabolism94–96,162,163. These studies revealed, that a Nur77 binding 
synthetic small molecule compound requires a benzene ring, the phenolic hydroxyl group 
and the acyl-chain, whereas the most important key feature regarding affinity and avidity 
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appeared to be the ester group162. The most interesting examples of the described small 
molecule compounds were ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate (TMPA) 
and 1-(3,4,5-trihydroxyphenyl)nonan-1-one (THPN), depicted in Figure 1. TMPA was shown 
to lower blood glucose levels as efficient as metformin in overweight (type II diabetes-prone) 
mice via abrogating the binding of Nur77 to LKB1 in the nucleus, thereby blocking the 
activation of AMPKa in hepatocytes96. THPN led to efficient induction of intrinsic apoptosis 
selectively in melanoma cell lines and reduced melanoma growth in vivo via inducing Nur77 
translocation to the mitochondrial outer membrane protein Nix94,95. Both compounds 
achieved their specific efficacy through a library-based change of the acyl group length 
compared to their parental compound cytosporone-B. Both, the TMPA and THPN –mediated 
effects were dependent on Nur77 and could not be compensated by other NR4A gene family 
members. 
 
Figure 1 Nur77 binding small molecule compounds cytosporone-B, TMPA and THPN 
a) Cytosporone-B (Csn-B, isolated from Dothiorella sp. HTF3, an endophytic fungus) has been 
identified as a direct agonist of Nur77 by binding to the Nur77 LBD resulting in apoptosis induction by 
augmentation of Nur77 transcriptional activity93. This resulted in reduced growth of gastric tumors and 
Zhang et al., Nature Chem. Biol. 2012
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increased gluconeogenesis in the liver109. b) TMPA (ethyl 2-[2,3,4-trimethoxy-6-(1-
octanoyl)phenyl]acetate) has been demonstrated to lower blood glucose levels as efficient as 
metformin in overweight (type II diabetes prone) mice via abrogating the binding of Nur77 to LKB1 in 
the nucleus, thereby blocking the activation of AMPKa in hepatocytes. This effect was not present in 
Nur77-/- mice96. c) THPN (1-(3,4,5-trihydroxyphenyl)nonan-1-one) has been demonstrated to efficiently 
induce intrinsic apoptosis selectively in melanoma cells via inducing translocation of Nur77 to the 
mitochondrial outer membrane protein Nix94,95. THPN treatment led to enhanced remission of B16 
melanomas in vivo. Again, this effect was not observed in Nur77-/- mice94,95. 
 
1.3 Potential of Nur77 binding small molecules to alter RICD in 
mature T-cells 
The majority of small molecule compound-based Nur77 research concentrated on promoting 
Nur77 function to result in cancer control or in correcting metabolic dysregulations. The 
unique biological function of Nur77 in humans, including the role of Nur77 in the human 
immune system, remains unknown, as no single patient with a loss of function/loss of 
expression mutation in Nur77 has been described yet. Notably, the potential of targeting the 
Nur77 associated RICD using Nur77 binding small molecule compounds in mature T-cells 
remains largely unassessed. 
The goal of my PhD thesis was to study the effect of previously described Nur77 binding 
small molecules on RICD in mature murine and human T-cells. 
 
 
Material and Methods 
Florian Marquardsen                                                                                      Immunodeficiency 9
2 Material and Methods 
Methods were all performed under optimized conditions according to established 
standardized operation protocols (SOP) in the lab. 
2.1 Cell culture 
2.1.1 Cell maintenance 
Cell culture was performed under sterile conditions in a laminar flow hood (Thermo Fisher). 
Cells and cell lines were maintained at 37°C in a standard 5% CO2 / 18% O2 atmosphere in 
culture incubators (Hera cell). Cells were all maintained with supplemented complete RPMI 
medium (Sigma-Aldrich) containing Penicillin-Streptomycin (Pen-Strep, Gibco), non-essential 
amino acids solution (NEAA, Gibco), additional glutamine (Glutamax, Gibco) and 10% fetal 
calf serum (FCS, Gibco). 
2.1.1.1 Freezing of cultured cells 
For long-time storage, cells were washed with ice cold medium and then re-suspended in 
freezing solution consisting of fetal calf serum (FCS, Gibco) containing 10% 
dimethylsulfoxide (DMSO, Sigma-Aldrich) at a cell density of 5-10 x 106 cells/ml. Cells were 
transferred into specialized freezing tubes (Sarstedt) and tubes were placed at -80°C for 24 
hours in a box, that is embedded in an isopropanol surrounded shell to preclude premature 
freezing. 24 hours later, freezing tubes were transferred into a liquid nitrogen tank to be 
stored for later experiments.  
Human primary T-cells were isolated and maintained from fresh blood samples of blood 
donors from the local blood donor center of the University Hospital Basel following informed 
consent. Cells were either isolated from whole buffy coats derived from 500 ml blood 
donations (pre-processed to enrich the leucocyte part by centrifugation) or from two or three 
EDTA tubes containing 7.5ml peripheral blood. 
2.1.2 Generation of splenocyte-derived murine primary T-cell blasts 
To generate murine primary T-cell blasts, 327tg mice, containing T-cells expressing a 
transgenic T-cell receptor-specific for the immunodominant MHC I restricted epitope (gp33-
41) of lymphocytic choriomeningitis virus (LCMV)164 were euthanized and spleens were 
removed. Splenocyte suspensions were created by careful application of pressure with a 
piston of a 5ml syringe and rinsing phosphate buffered saline (PBS) containing 2% FCS 
through 50µm pore size cell strainers (Corning). Subsequent incubation in hyperosmotic 
ACK lysis buffer (Qiagen) was performed to lyse erythrocytes. For expansion of LCMV-
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specific T-cells, 2 x 106 splenocytes/ml were stimulated with LCMV derived gp33-41 peptide 
(1nM in vitro, IBA Life Science, Germany) plus recombinant IL-2 (300IU/ml, Proleukin®, 
Novartis,) in 25cm2 culture flasks (Axonlab). T-cell blasts were expanded 1:1 every 2-3 days 
with fresh medium containing IL-2. 
2.1.3 Isolation of human peripheral blood mononuclear cells 
(PBMC) 
Peripheral blood mononuclear cells (PBMC) were directly isolated and maintained from fresh 
blood samples of blood donors from the local blood donor center of the University Hospital 
Basel following informed consent. EDTA blood- or buffy coat-derived PBMC were density-
separated by loading EDTA blood onto the lymphoprep density gradient medium (Axis 
Shield) and centrifuged for 20 min at 400g with centrifuge deceleration efficacy set to 20%. 
After centrifugation, PBMC appeared as a white colored ring above the lymphoprep reagent. 
After transfer of PBMC into a 50ml Falcon tube and washing in PBS, erythrocyte lysis was 
performed by resuspension in one ml of hyperosmotic ACK erythrocyte lysis buffer (Qiagen) 
for five minutes. Subsequent washing with PBS was performed to dilute the lysis buffer and 
to remove leftovers of erythrocytes and cell debris. PBMC were then counted using a cell 
counter machine (NanoEnTek) and were then used directly for experiments or used to 
generate human primary T-cell blasts. 
2.1.4 Generation of PBMC-derived human primary T-cell blasts 
To study T-cell apoptosis and RICD in particular, primary human T-cell blasts were 
generated for re-stimulation experiments. PBMC were seeded into 96-well round bottom 
plates (Starlabs) with a cell density of 2-3 x 106 cells/ml in complete medium. PBMC derived 
T-cells were activated by adding 5 µg/ml phytohemagglutinin (PHA, isolated from the plant 
Phaseolus Vulgaris, Sigma Aldrich). In addition, human IL-2 (300IU/ml, Proleukin®, Novartis) 
was added to the medium. Every 4-7 days, cells were expanded 1:1 by adding the same 
volume of fresh complete medium containing fresh IL-2. After 2-3 rounds of expansion, 
primary T-cell blasts were used for re-stimulation experiments. Flow-cytometric analysis 
showed that primary T-cell blasts consisted of > 95% CD3+ T-cells. While the CD4+/CD8+ T-
cell ratio was normally >1 in PBMC-derived T-cells, the CD4+/CD8+ ratio was typically <1 in 
primary T-cell blasts (data not shown). 
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2.2 Cell biological methods 
2.2.1 In vitro re-stimulation of primary T-cell blasts 
To measure re-stimulation cell death (RICD) in primary T-cell blasts, cells were enriched for 
live cells by performing a ficoll-based separation or alternatively by using a bead-based 
negative selection (dead cell removal kit, Miltenyi) according to the manufacturer’s protocol. 
Cells were seeded at a cell density of 2,5 x 106 cells/ml medium into 96-well U bottom plates 
(200μl final volume). T-cell re-stimulating stimuli or reagents were added as outlined below 
(Table 1). Nur77 binding small molecule compounds (cytosporone B, TMPA or THPN) were 
added directly before applying the stimuli at the indicated concentrations. Specific inhibitors 
of signaling were added 30 minutes before re-stimulation (if not further specified). The 
standard incubation time before assessing RICD was four hours. 
 
Table 1 Stimuli or reagents used for re-stimulation bioassays 
Reagent or antibody (clone) [c] final Company 
PMA (Phorbol ester) 5ng/ml Sigma-Aldrich 
PHA (Phytohemagglutinin) 0,5 – 5 µg/ml Sigma-Aldrich 
Staurosporine (Indolcarbazole) 0,5 - 2 µM Sigma-Aldrich 
Anti CD28 (CD28.2) 0,5 – 5 µg/ml Biolegend 
Anti CD3 (OKT3) 0,5 – 5 µg/ml Biolegend 
Anti FAS (EOS9.1) 0,5 – 5 µg/ml Biolegend 
Recombinant FASL 50 – 500 ng/ml ebioscience 
gp33-41 peptide 1 - 10 nM Iba lifesciences 
OVA peptide 1 – 10 pM Anaspec Inc. 
Cytosporone-B 1 – 100 µM Sigma 
TMPA  1 – 100 µM Merck 
THPN 0.5 – 50 µM Merca Chem 
U0126 1 µM Sigma 
PD184352 10 µM Sigma 
 
2.2.2 Transfection of cells with siRNA 
To investigate the causative role of a single gene and its encoded protein on T-cell RICD, 
genes of interest were knocked down by targeting them with small interfering RNA (siRNA). 
These siRNAs were transfected into the cells by electroporation using the AMAXA device 
(Lonza). T-cell blasts were prepared for transfection in specialized glass cuvettes (Lonza) by 
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washing and subsequent resuspension in transfection solution (transfection kit for activated 
T-cells or cell lines, Lonza). The specific siRNA and a non-specific control siRNA (mix of 
several unspecific sequences, Qiagen) was diluted with transfection solution at the 
concentration specified in Table 2. Specific siRNA were used in combination with total 
concentration of 100nM. T-cell blasts were afterwards re-suspended with fresh medium and 
rested for 24 hours before they were used for experiments. 
 
Table 2 siRNA used for transfection 
siRNA target siRNA [c] final Company 
Nur77 (NR4A1) Flexitube siRNA (2) 25nM Qiagen 
Nur77 (NR4A1) Flexitube siRNA (3) 25nM Qiagen 
Nur77 (NR4A1) Flexitube siRNA (5) 25nM Qiagen 
Nur77 (NR4A1) Flexitube siRNA (6) 25nM Qiagen 
Nor1 (NR4A3) Gen Solution siRNA (2) 25nM Qiagen 
Nor1 (NR4A3) Gen Solution siRNA (4) 25nM Qiagen 
Nor1 (NR4A3) Gen Solution siRNA (5) 25nM Qiagen 
Nor1 (NR4A3) Gen Solution siRNA (6) 25nM Qiagen 
Control siRNA AllStars negative control 100nM Qiagen 
 
2.3 Flow Cytometry 
Flow-cytometry was performed to assess T-cell proliferation and T-cell apoptosis in specific 
T-cell subpopulations. Flow cytometric analysis was performed with the flow-cytometers 
Accuri (BD bioscience), Cytoflex (Beckman Coulter) or Fortessa (BD bioscience). 
2.3.1 Flow-cytometric phenotyping based on surface protein 
expression 
For flow-cytometric phenotyping of freshly isolated PBMC derived T-cells, cells were seeded 
at a density of 2-3 x 106 cells/ml and washed two times with PBS/1% FCS (FACS buffer). 
Washed cells were re-suspended in 100 µl of FACS buffer containing a mixture of 
fluorescent staining antibodies at a dilution of 1:100 (if not further specified). Incubation with 
the staining antibody solution was 30 minutes at room temperature (RT) or at four degrees. 
Most staining antibodies were directly conjugated with a fluorochrome. For staining with non-
conjugated antibodies, a two-step staining was performed. Here, a fluorochrome-labeled 
secondary antibody against the immunoglobulin isotype of the non-labeled primary antibody 
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was used to generate a fluorescence signal for the flow-cytometric analysis. Non-specific 
isotype antibodies were used to define the background fluorescence signal. 
To correct for overlaps of the fluorochrome emission spectra, that could not be avoided by a 
mathematical compensation, a single stain sample of every used fluorochrome was prepared 
for every flow-cytometric analysis that used more than two lasers. A list of antibodies used 
for flow-cytometric analysis is given in Table 3. 
 
Table 3 Antibodies used for staining of surface proteins 
Epitope human (clone) [c] final Fluorochrome Company 
Primary antibodies    
CD3 (UCHT1) 0.5 µg/ml PE, APC, Alexa700 Biolegend 
CD8 (SK1) 0.5 µg/ml Alexa488, PE-Cy7 Biolegend 
CD4 (SK3) 0.5 µg/ml PE, PE-Cy7 Biolegend 
Epitope murine (clone) [c] final Fluorochrome Company 
Primary antibodies    
CD3 (17A2) 0.2 µg/ml PE ebioscience 
CD8 (53-6.7) 0.2 µg/ml Pacific Blue ebioscience 
 
2.3.2 Phenotyping of splenocyte-derived murine LCMV-specific 
transgenic primary T-cells and T-cell blasts 
Expression of the transgenic TCR-a (Va2) and TCR-β (Vβ8.1), derived from a T-cell line 
specific for the immunodominant MHC I restricted epitope gp33-41 of lymphocytic 
choriomeningitis virus (LCMV)165,166, in 327tg mice was verified by flow-cytometric analysis. 
Murine splenocytes were stained with fluorochrome-labeled monoclonal antibodies specific 
for TCR Va2 and Vβ8.1 (Table 4) according to 2.3.1. 
 
Table 4 Antibodies used for flow-cytometric phenotyping of 327tg mice 
Epitope murine (clone) [c] final Fluorochrome Company 
Primary antibodies    
Va2 TCR 2,5 µg/ml FITC BD Pharmingen 
Vβ8.1 TCR 2,5 µg/ml Alexa647 Biolegend 
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2.3.3 Assessing apoptosis by flow-cytometry using annexinV 
binding 
Apoptotic cells, in contrast to live cells, are characterized by phosphatidylserine (PS) 
expression at the outer cell membrane167. At high calcium concentrations, annexinV binds 
specifically to phosphatidylserine. Therefore, fluorochrome-coupled annexinV can be used to 
identify apoptotic cells by flow-cytometry. To assess T-cell apoptosis by flow-cytometry, T-
cell blasts were washed two times with annexinV binding buffer (Biolegend) and 
subsequently stained with fluorochrome-labeled annexinV diluted 1:100 in annexinV binding 
buffer for 30 minutes at RT.  
Additionally, 7-Aminoactinomycin (7-AAD) was used to distinguish early apoptotic cells 
(annexinV+) from late apoptotic or necrotic cells (annexinV+ 7-AAD+) (Table 5, data not 
shown). Co-staining with antibodies specific for cell surface proteins was performed in the 
same buffer (according to 2.3.1). 
 
Table 5 Reagents used for cytometry-based assessment of apoptotic cells 
Reagent [c] final Fluorochrome Company 
annexinV 1 µg/ml FITC, PE, APC Biolegend 
7-AAD 0.5 µg/ml autofluorescent ebioscience 
 
2.3.4 Flow-cytometric analysis of intracellular, nuclear and 
phosphorylated proteins 
RICD associated changes in protein biosynthesis were assessed by flow-cytometric analysis. 
T-cell blasts were fixed using fixation buffer (Fix/Perm, BD bioscience) according to the 
manufacturer’s protocol (BD bioscience). Saponin based buffers (BD Perm/wash) are milder 
than methanol based buffers (BD Perm III), the latter leading to linearization of proteins 
which deteriorates binding of many flow-cytometry antibodies due to destruction of the 
secondary and tertiary protein structures. Linearization of proteins is however required to 
measure phosphorylation of proteins by flow-cytometry. Methanol based buffers (Perm III, 
BD bioscience) but also saponin based buffers (Perm/wash, BD bioscience) permeabilize the 
nuclear membrane. Therefore, methanol- or saponin based buffers were used to flow-
cytometrically quantify intranuclear proteins while flow-cytometric assessment of protein 
phosphorylation required the use of methanol based buffers.  
Following fixation and permeabilization, T-cell blasts were stained with fluorochrome 
conjugated antibodies in the required buffer for 30-45 minutes at RT. For non-conjugated 
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antibodies, secondary fluorochrome-labeled antibodies were used. Table 6 summarizes the 
utilized antibodies. 
 
Table 6 Antibodies used for intracellular-, nuclear- and phospho-protein staining 
Epitope human (clone) [c] final Fluorochrome Company 
Primary antibodies    
Nur77 (D63C5) 0.7 µg/ml - Cell Signaling 
p-Nur77 Ser351 (D22G5) 0.6 µg/ml - Cell Signaling 
Rabbit mAb IgG Isotype Ctrl 
(DA1E) 
Adjusted to 
experiment 
- Cell Signaling 
SAP (1C9)  4 µg/ml - Abnova 
IgG 1 𝜅 Isotype Ctrl 4 µg/ml - Abnova 
IFNɣ (B27) 2 µg/ml PE biolegend 
TNFa (MAb11) 1 µg/ml PE ebioscience 
Secondary antibodies    
Fab2 fragment goat anti rabbit 
IgG 
0.75 µg/ml Alexa647 Jackson 
Immunoresearch 
Epitope murine (clone) [c] final Fluorochrome Company 
Primary antibodies    
IFNɣ (MOB-47) 4 µg/ml PE Biolegend 
TNFa (MP6-XT22) 2 µg/ml FITC Biolegend 
Nur77 (12.14) 1 µg/ml PE ebioscience 
Mouse IgG 1 𝜅 Isotype Ctrl 1 µg/ml PE ebioscience 
 
2.3.5 Assessing primary T-cell proliferation by flow-cytometry using 
CFSE 
To measure T-cell proliferation kinetics in vitro, cells were labeled with Carboxyfluorescein 
succinimidyl ester (CFSE), a fluorescent cell staining dye, that covalently couples to 
intracellular proteins containing lysine or other amine residues. Due to its covalent coupling, 
the dye retains in the cell and is diluted with every cell division. Thus, loss of fluorescence is 
directly correlated with cell proliferation. To assess cell proliferation in primary T-cells, 3 x 106 
PBMC/ml were washed two times with PBS and subsequently stained with CFSE containing 
PBS (5 µM, Thermo Fisher) for ten minutes at 37°C. Unbound dye was removed by washing 
the cells twice in ice cold complete medium. Cells were then stimulated with anti-CD3/CD28 
antibodies (5 µg/ml each, Biolegend) or PHA (5 µg/ml, Sigma Aldrich) to activate T-cells. In 
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addition, IL-2 (300IU/ml, Proleukin®, Novartis) was added to the medium. For assessment of 
T-cell proliferation, CFSE fluorescence of CD3+ T-cells was analyzed by flow-cytometry. 
2.3.6 Assessing mitochondrial membrane potential by flow-
cytometry using TMRE 
Intrinsic apoptosis pathways as described above involves mitochondrial damage by MOMP. 
This membrane potential drop during permeabilization can be measured by incubating cells 
with a fluorescent dye (TMRE), that accumulates in intact mitochondria due to its positive 
charge. Depolarized or disrupted mitochondria cannot anymore sequester TMRE within 
mitochondria. Therefore, TMRE can be used to flow-cytometrically assess the drop of the 
mitochondrial membrane potential in apoptotic cells. Four hours after T-cell RICD induction, 
T-cell blasts were cultured for additional 30 minutes in medium containing 100 nM TMRE 
according to the manufacturer’s protocol (Immunochemistry Technologies). Following 
washing, T-cell blast-intrinsic TMRE fluorescence was measured by flow-cytometry as 
described in 2.3.1. 
2.3.7 Assessing caspase activation by flow-cytometry using 
FLICA® 
Intrinsic and extrinsic apoptosis involves proteolytic cleavage of effector caspases leading to 
caspase activation Caspase activation can be measured by incubating re-stimulated T-cells 
with the fluorochrome-labeled specific caspase inhibitors (FLICA) FAM-LEHD-FMK (caspase 
9-specific) or FAM-LETD-FMK (caspase 8-specific). The cell-permeable, fluorescent 
reagents become covalently coupled to the activated caspases. Therefore, cellular 
fluorescence is directly linked to activation of caspases during T-cell RICD.  
Four hours following induction of T-cell RICD, cells were incubated with medium containing 
50 - 200 nM of the FLICA®-reagent for additional 30 minutes at 37°C according to the 
manufacturer’s protocol (Immunochemistry Technologies). Subsequently, cells were stained 
and analyzed by flow-cytometry as described in 2.3.1. 
2.4 Molecular biological methods 
All molecular biological methods to analyse RNA and DNA were performed under non-sterile 
but clean and nuclease free conditions. Basis material for RNA or genomic DNA extraction 
were cell lysates (1 – 5 x 106 cells) derived from frozen cell pellets or from fresh cell pellets, 
that were frozen after re-suspension in Trizol reagent (ambion, life technologies) at -20°C. 
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2.4.1 RNA extraction from cell lysates 
For RNA extraction, cell lysates re-suspended in Trizol reagent were thawed and chloroform 
was added at 20% of total volume. RNA isolation was performed using an QIAamp RNA 
blood mini kit according to the manufacturer’s instructions (Qiagen). Final elution volume was 
25 – 50 µl in nuclease free water. RNA concentration was measured with a nanodrop 
machine (Thermo Fisher Scientific). 
2.4.2 Reverse transcription 
Prior to reverse transcription, RNA was first digested with a DNAse I Amplification Grade Kit 
(Sigma) at 37°C for 30 minutes in PCR tubes (Sarstedt). DNAse was subsequently 
inactivated for 10 minutes at 65°C. Then, annealing of random primers (Promega) was 
allowed at 70°C. A master mix with all essential reverse transcription reaction reagents was 
applied directly with the annealed RNA-Primer mix including a control condition with 
nuclease free water. Reverse transcription using the GoTaq G2 DNA Polymerase (Promega) 
was finally performed in a TProfessional TRIO PCR Thermocycler (Core Life Sciences) 
according to manufacturer’s protocol (GoScript Reverse Transcription System). cDNA was 
stored at 4°C or directly used for analysis. 
2.4.3 Quantitative real time PCR (qPCR)  
cDNA was directly used for qPCR analysis. qPCR was performed using a Sybr Green® 
method (Promega). Specific primers for qPCR were designed with a free open source 
software Primer Blast of the NCBI databank. The FASTA-file from the NCBI gene card was 
used as a matrix to create specific oligos, that overlapped at least two exons and had a 
predicted product size of not more than 150 base pairs. Primer length was around 20 – 23 
bases (Table 8). Primer oligos were synthesized by a company (Microsynth). In addition, 
mRNA levels of at least two reference genes were analyzed in parallel. Examples for 
reference genes were GAPDH and ACTIN (for unstimulated conditions) or 18S and IPO8 (for 
stimulated conditions). Finally, cDNA expression levels measured in re-stimulated T-cells 
were compared in relative units (fold change) to transcription levels under non-stimulated 
conditions. All samples were additionally normalized to the expression levels of the reference 
(housekeeping) genes. The PCR was prepared according to the manufacturer’s protocol 
(Promega). A GoTaq qPCR Master Mix (Promega), containing all essential reaction reagents 
was used together with the sample cDNA (and a control condition with nuclease free water) 
and the specific primers (forward and reverse) in FAST qPCR® 96-well plates (R&D 
Systems). The plate was sealed with a foil to prevent evaporation and qPCR was performed 
in a qPCR cycler ABI machine (Applied biosystems, Thermo Fisher Scientific) (settings are 
Material and Methods 
Florian Marquardsen                                                                                      Immunodeficiency 18
displayed in Table 7). A FAST qPCR with 40 cycles (two-hours runtime) and a melting curve 
was performed.  
QPCR data were finally saved on a common lab server for later analysis. For data analysis, 
quantification equation based on a publication by W. Pfaffl was used168. 
 
Table 7 qPCR program settings 
Temperature Time Cycles 
50°C 2 min 1 
95°C 10 min 1 
95°C 15 sec 
40 
60°C 1 min 
 
Table 8 primer sequences used for qPCR 
Gene Forward Reverse 
Human   
NR4A1 GATCGGTCCCCAAAGGATG TGAGGGTCTGGGCATAGAA 
NR4A3 TGCAAAGCTGTCCATTACAC GCATCCTCCACGAGCAAGT 
SH2D1A GGCAGCTATTTGCTAGGGA TCTGTCTGGGAACTCGGTA 
SH2D1B1 GACAGCGAGTCGATCCAGG ACCCGTGTTTCCTCTGAAG 
SLAMF1 GCTCCTCTCCTTGACTTCG CCGGAGAATCTTGGGCAGT 
SLAMF6 CTCTCGGACTGAGAACGCA CGCAGGCTGAATTGTCTAC 
Murine   
Nr4a1 AGTTGGGGGAGTGGCTAGA GCTCGTTGTGGTGTTCCAT 
Nr4a3 ACTGCATCTTGGTTTGCAG TCTTCCAATCTATGCCACTTG 
Sh2d1a CGAGTGTCCCAGCAGAAAA GGATACGCAGAGGCGTCAC 
 
2.4.4 Genomic DNA extraction and endpoint PCR 
For genotyping or DNA sequencing, genomic DNA was extracted from dried, frozen cell 
pellets or from mouse tissue (earpunch biopsies) according to the manufacturers protocol 
(Qiagen). For DNA extraction, a rapid protocol with a ready-to-use master mix was used 
(Kapa biosystems). DNA extraction was performed at 56°C on a shaker using the Kapa 
express extract buffer. Genomic DNA could subsequently be used for endpoint PCR or 
stored for later analysis at 4°C. 
For endpoint PCR, the master mix with the specific primers to amplify the sequence of 
interest was added. Amplification was performed using the GoTaq G2 DNA Polymerase 
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(Promega). The PCR program (according to manufacturer’s protocol, Promega) was 
performed in a TProfessional TRIO PCR Thermocycler (Core Life Sciences) (Table 9). 
Primers were designed according to 2.5.4 (Table 6). Primer sequences specific for detection 
of Nur77 knock-out mice were used as described in previous studies reporting these mice160 
(Table 10). 
 
Table 9 endpoint PCR program settings 
Temperature Time Cycles 
95°C 2 min 1 
95°C 20 sec 
38 62°C 20 sec 
72°C 45 sec 
72°C 5 min 1 
 
Table 10 Primer sequences used for Nur77 genotyping 
Gene Forward Reverse 
Murine   
Nr4a1 TCATGGACGGCTACACAG GTAGGCATGGAATAGCTC 
 
2.5 RNA Sequencing 
RNA sequencing experiments were performed in RNA samples derived from re-stimulated T-
cells derived from 327tg mice, where most CD8+ T-cells are specific for the immunodominant 
lymphocytic choriomeningitis virus (LCMV) peptide gp33-41164–166. LCMV-specific CD8+ T-cell 
blasts were re-stimulated in vitro for four hours using the gp33-41 peptide (1nM) in the 
presence or absence of titrated amounts of TMPA. The use of transgenic T-cells allowed a 
standardized experimental setup in which differences due to genomic variance could be 
minimized. 
2.5.1 Sample preparation and transcriptome analysis 
Splenocytes from four different 327tg mice were in vitro stimulated with the LCMV derived 
gp33-41 peptide in the presence of IL-2 (300IU/ml). 8 days later, expanded T-cell blasts were 
re-stimulated with gp33-41 peptide in the absence or presence of TMPA (5 and 50 μM). All 
four 327tg mice were processed on four different days, including the expansion of 
splenocytes and the final re-stimulations assays.  
For generation of RNA, 1,5 x 106 cells were lysed in a special lysis buffer for RNA extraction 
(Machery-Nagel). Lysis volume was 200 µl. The lysates were directly frozen at -80°C. RNA 
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extraction and the subsequent preparation for RNA sequencing, including the creation of an 
RNA library was outsourced to the sequencing facility at the Biocentre of Basel, headed by 
Phillipe Demougin. RNA sequencing was then performed at the core facility of the DBSSE 
Basel. The statistical evaluation and the implementation of the sequencing raw data into a 
specific analysis online tool was performed by Julien Roux, bioinformatics core facility of the 
Department of Biomedicine Basel. Detailed and structured comparison between unstimulated 
and stimulated conditions on the one hand, and untreated and treated conditions on the 
other hand, regarding significance and multiple component analysis, was performed with 
Microsoft Excel 2016, Prism7 and curated databases for pathway mapping analyzes based 
on pathwayseq169. 
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3 Results 
3.1 Nur77 is rapidly induced during primary human T-cell RICD 
preceding intrinsic apoptosis induction 
Beside metabolism85, insulin sensitivity170, obesity171 and onset and progression of various 
cancer types156, a repeatedly demonstrated function of Nur77 was to promote apoptosis 
during thymocyte development and during T-cell RICD82,86,151. The exact role of Nur77 in re-
stimulated mature human T-cells however has not yet been assessed yet. 
3.1.1 Experimental assessment of RICD in primary human T-cell 
blasts 
To assess the role of Nur77 in RICD in mature human T-cells, assays were established to 
measure apoptosis following re-stimulation of expanded primary human T-cell blasts (see 
methods). Apoptosis induction was monitored using different flow-cytometry based methods 
(representatively shown in Figure 2). These consisted of a) quantifying annexinV binding to 
exposed phosphatidylserine at the outer T-cell membrane, b) assessment of mitochondrial 
outer membrane potential by incubating re-stimulated T-cells with the fluorescent, 
mitochondria-affine and mitochondrial potential-sensitive compound TMRE and c) flow-
cytometric assessment of fluorescently-labeled caspase 9 inhibitor (FLICA)-binding to 
activated caspase 9, the initiator caspase of the intrinsic apoptosis signaling pathway. In the 
absence of re-stimulation, primary CD3+ human T-cell blasts displayed as two prominent cell 
populations based on forward- (FSC) and side scatter (SSC) flow-cytometric analysis. These 
populations represent ‘live’ (high FSC) vs. ‘dead’ (low FSC) T-cell populations based on 
apoptosis marker expression (Figure 2). Already four hours after re-stimulation of primary T-
cell blasts with the phorbol ester PMA (Phorbol-12-myristat-13-acetat), the ‘live’ population 
was relatively reduced and a relative increase of the ‘dead’ T-cell population was observed. 
Within the ‘live’ gate, PMA induced apoptotic changes on a subfraction of T-cell blasts, while 
almost all cells within the ‘dead’ gate expressed an apoptotic phenotype (Figure 2). Based 
on these results, all subsequent measurements of T-cell apoptosis are based on flow-
cytometric analysis of T-cells within the ‘live’ gate. 
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Figure 2 Flow-cytometric assessment of apoptosis in primary human T-cell blasts 
Primary human T-cell blasts were re-stimulated with PMA or left non-stimulated for four hours in 
medium. Cells were gated on CD3+/CD8+ expression for flow-cytometric analysis of CD8+ T-cell 
apoptosis. Forward- (FSC) vs. side scatter (SSC) analysis revealed two populations of T-cells, which 
could be attributed to ‘live’ vs. ‘dead’ cell fractions based on the cell size and expression of markers of 
apoptosis (see below). Apoptotic cells were defined as annexinV+, activated Caspase 9+ and TMRElo. 
a) PMA re-stimulation induced a subfraction of apoptotic, annexinV+ CD8+ T-cells within the ‘live’ gate. 
Within the ‘dead’ gate, almost all cells were annexinV+. b) For assessment of caspase 9 activity, T-cell 
blasts were incubated with the fluorochrome-labeled caspase 9-specific inhibitor FAM-LEHD-FMK 
(100 nM) for the last 30 minutes of culture according to the manufacturer’s protocol (Immunochemistry 
technologies) and subsequently stained for CD3 and CD8 prior to flow-cytometric analysis. Following 
PMA stimulation, a subfraction of T-cell blasts displayed activated caspase 9 (see representative 
histograms). c) For assessment of T-cell blast intrinsic mitochondrial potential, T-cells were incubated 
at 37°C for the last 30 minutes of culture in medium containing TMRE (100nM) according to the 
manufacturer’s protocol (Immunochemistry technologies) and subsequently stained for CD3 and CD8 
before analysis by flow-cytometry. PMA re-stimulation for four hours was associated with increased 
frequencies of TMRElo T-cell blasts, indicative for loss of mitochondrial outer membrane potential. 
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3.1.2 Nur77 induction and phosphorylation in re-stimulated primary 
human T-cell blasts 
Nur77 has been reported to exert its functions depending on tissue context, in which it is 
expressed and on the subcellular expression compartment119. Whereas Nur77 is 
constitutively expressed in cancer cell lines155, its expression in T-cells requires  signaling via 
the T-cell receptor82. To assess Nur77 and its role in T-cell RICD, we monitored Nur77 
expression by flow-cytometry early after re-stimulation. (Figure 3). 
Primary human T-cell blasts were re-stimulated in vitro with PMA to induce intrinsic 
apoptosis. In vitro incubation with an agonistic anti-FAS antibody induced extrinsic apoptosis 
as control. In a representative experiment, both conditions induced considerable T-cell 
apoptosis within four hours (PMA 61% annexinV+ vs. aFAS 49% annexinV+). However, 
Nur77 expression was only detected in cells re-stimulated with PMA (55% Nur77+), while 
aFAS treatment induced apoptosis in the absence of Nur77 expression (Figure 3a). The 
results observed following aFAS in vitro treatment also suggested that T-cell intrinsic Nur77 
expression is not a per se consequence of T-cell apoptosis (Figure 3a). 
To test, which major kinase cascade regulates early Nur77 induction following PMA re-
stimulation, two inhibitors for the mitogen activated protein kinases (MAPK) MEK/ERK 
pathway (U0126172 and PD184352173) were incubated with primary human T-cell blasts prior 
to induction of RICD . Both inhibitors almost completely blocked Nur77 induction two hours 
following PMA re-stimulation in primary human T-cells (Figure 3b).  
In keeping, activation of caspase 9 following PMA induced T-cell re-stimulation was reduced 
in the presence of these two inhibitors (Figure 3c).  
Thus, Nur77 was rapidly induced following MEK/ERK signaling in re-stimulated primary 
human T-cell blasts, correlating with apoptosis induction via the intrinsic apoptosis pathway. 
Next, we experimentally tested whether direct targeting of Nur77 with a Nur77 LBD binding 
small molecule compound (TMPA96) influenced Nur77 expression and Nur77 
phosphorylation in re-stimulated human T-cell blasts. Nur77 phosphorylation has been 
reported to drive Bcl-2-dependent apoptosis in cancer cells143. Treatment of primary human 
T-cell blasts with TMPA (low and high dose (10µM + 50µM)) during re-stimulation did not 
impact on Nur77 expression as analyzed by flow-cytometry, neither in PMA re-stimulated 
cells, nor in cells re-stimulated by TCR crosslinking with an agonistic anti-CD3 antibody 
(aCD3, clone OKT3) (Figure 3d). TCR crosslinking by agonistic aCD3 antibody led to 
impaired Nur77 protein induction compared to PMA re-stimulation (Figure 3d). FAS 
crosslinking did not induce Nur77 expression, neither in the presence nor in the absence of 
TMPA (Figure 3d). Nur77 phosphorylation was also assessed by flow-cytometry using an 
antibody detecting the phosphorylation of a Serine at position 351. Similar to total Nur77 
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protein expression, Nur77 phosphorylation was augmented in PMA re-stimulated T-cell 
blasts compared to TCR crosslinking, while no phosphorylation could be detected as a 
consequence of FAS crosslinking (Figure 3d). Treatment with low dose TMPA (10µM) did 
not impact on Nur77 phosphorylation, whereas high dose TMPA reduced RICD associated 
Nur77 phosphorylation, both following PMA or aCD3 re-stimulation (Figure 3d). In summary, 
the Nur77 binding small molecule compound TMPA did not alter Nur77 induction during T-
cell RICD, while reduction of Ser351 phosphorylation was dose-dependent.. 
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Figure 3 Nur77 induction following MEK/ERK driven T-cell activation 
a) Primary human T-cell blasts were re-stimulated with PMA, treated with agonistic FAS-specific 
monoclonal antibody (aFAS) or left unstimulated for two hours in RPMI medium. T-cell blasts were 
subsequently assessed for Nur77 expression with a two-step staining protocol and flow-cytometric 
analysis according to 2.3.4. For assessment of T-cell RICD, T-cell blasts were re-stimulated with PMA, 
treated with agonistic aFAS antibody or left unstimulated for four hours and subsequently stained with 
annexinV and analyzed by flow-cytometry according to 2.3.3. Results from representative experiments 
are shown. b) Primary human T-cell blasts were incubated with the MEK inhibitors U0126 (1 µM) and 
PD184352 (10 µM) for 30 minutes prior to re-stimulation with PMA. Nur77 expression was analyzed by 
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flow-cytometry two hours after re-stimulation. c) Caspase 9 activation was assessed by flow-cytometry 
four hours after PMA re-stimulation according to 2.3.6. Primary human T-cell blasts were incubated 
with the MEK inhibitors U0126 (1 µM) and PD184352 (10 µM) for 30 minutes prior to re-stimulation as 
indicated. Representative histogram plots are shown. d) To assess Nur77 expression and Nur77 
phosphorylation, primary human T-cell blasts were re-stimulated with PMA, agonistic anti-CD3 
monoclonal antibody (aCD3, clone OKT3), treated with agonistic FAS-specific monoclonal antibody 
(aFAS) or left unstimulated in medium. The Nur77 binding small molecule compound TMPA was 
added at indicated concentrations prior to T-cell stimulation. Two hours later, expression of Nur77 or 
phospho-Nur77 (Ser351) was assessed using specific monoclonal antibody staining followed by flow-
cytometric analysis according to 2.3.4. The summary graph shows mean and standard deviation of 
experiments performed using T-cell blasts derived from N=3 healthy donors. 
Cells were gated on CD3+/CD8+ expression for flow-cytometric analysis. Statistics were performed 
using a two-way-ANOVA test; ns indicates non-significant changes, * = p<0,05, ** = p<0,01, *** = 
p<0,001. 
 
3.2 Assessment of human T-cell RICD in the presence of Nur77 
binding small molecule compounds 
To date, no endogenous ligand has been described for Nur77. Several studies have 
investigated the pro-apoptotic role of Nur77 by targeting the Nur77-LBD with small molecule 
compounds to modulate its function93,95,96,162. All of these studies have analyzed apoptosis 
induction in cancer cell lines. Direct targeting of Nur77 in primary murine and human T-cells 
has not been addressed yet. To test, whether previously described small molecule 
compounds impact on RICD in primary human T-cells, apoptosis was monitored following re-
stimulation in the presence vs. absence of Nur77 targeting small molecule compounds 
(Figure 4). 
3.2.1 TMPA and THPN impair human T-cell RICD  
Primary human T-cell blasts were in vitro re-stimulated with PMA and apoptosis was 
monitored by annexinV staining and flow-cytometry four hours later. Non-re-stimulated cells 
served as a control (Figure 4). Cytosporone-B, TMPA and THPN were titrated into T-cell 
blast cultures at different concentrations before re-stimulation to generate in vitro dose-
response curves of each compound. Cytosporone-B and THPN induced re-stimulation-
independent T-cell death at concentrations above 50µM (Figure 4a). In contrast, TMPA did 
not induce spontaneous T-cell death even at high concentrations. At high doses, 
cytosporone-B reduced T-cell RICD, however, since these concentrations also induced non-
re-stimulation induced apoptosis, the significance of this finding remained unclear (Figure 
4a). TMPA significantly reduced T-cell RICD in a dose-dependent manner, starting at 10µM. 
THPN also significantly reduced T-cell RICD  at concentrations of 1 and 10µM. Higher 
concentrations of THPN, similar to cytosporone-B, induced non-re-stimulation associated T-
cell apoptosis (Figure 4a). 
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TMPA and THPN were further analyzed for their ability to reduce T-cell RICD in N=8 healthy 
donors to proof consistency of efficacy. Both, TMPA and THPN demonstrated consistent, 
dose-dependent reduction of T-cell RICD (Figure 4b). 
Since TMPA did not display any cytotoxicity and it revealed the strongest impairment of T-
cell RICD in vitro, we focused on TMPA as a Nur77 LBD binding compound for subsequent 
studies.  
TMPA significantly reduced T-cell RICD following PMA but also following TCR crosslinking 
via an agonistic aCD3 antibody. On the other hand, TMPA did not significantly alter T-cell 
apoptosis induced by agonistic anti FAS antibody (Figure 4c). To test, whether TMPA also 
reduced antigen-specific RICD in primary human T-cells, EBV-specific T-cell blasts were 
expanded and re-stimulated with an EBV peptide pool to induce RICD. TMPA reduced RICD 
significantly in EBV peptide pool- and also PMA re-stimulated EBV-specific T-cell blasts 
(Figure 4d).  
Taken together, TMPA consistently reduced T-cell RICD in both, polyclonal T-cell blasts and 
in EBV peptide-specific T-cell blasts. In contrast, FAS mediated, extrinsic T-cell blast 
apoptosis was not altered in the presence vs. absence of TMPA treatment, indicating that 
TMPA specifically blocked TCR-signaling induced, intrinsic RICD in primary human T-cells 
(Figure 4e). 
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Figure 4 Effect of Nur77-binding small molecule compounds on T-cell RICD 
a) - c) Primary human T-cell blasts ((a) N=4, b), c) N=8)) were re-stimulated with PMA, treated with 
agonistic anti-CD3 monoclonal antibody (clone OKT3), agonistic FAS-specific monoclonal antibody 
(aFAS) or left unstimulated. Small molecule compounds cytosporone-B, TMPA and THPN were added 
at the indicated concentrations prior to re-stimulation. In c) and d) TMPA was used at a concentration 
of 10 µM. Four hours later, CD3+CD8+ T-cell blasts were assessed for T-cell RICD using annexinV 
staining and flow-cytometric analysis according to 2.3.3. In b) representative histogram plots of 
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annexinV fluorescence are depicted together with a summary graph displaying results measured in T-
cell blasts derived from individual blood donors d) EBV-specific T-cell blasts (N=4) were initially 
stimulated with an EBV peptide-pool and subsequently flow-sorted for IFNɣ	 positive T-cell blasts. 
These cells were then in vitro re-stimulated using either EBV peptide pool or PMA. Four hours later, T-
cell RICD was measured by annexinV staining and flow-cytometric analysis according to 2.3.3. e) 
Relative reduction of T-cell RICD in the presence compared to the absence of 10 µM TMPA is 
depicted (% of annexinV+ cells in the presence vs. absence of Nur77 binding small molecule 
compounds). All cells were gated for CD3+/CD8+ expression for flow-cytometric analysis of apoptosis. 
Statistics were performed using two-way- ANOVA test, ns indicates non-significant changes, * = 
p<0,05, ** = p<0,01, *** = p<0,001. Mean and standard deviation are shown. 
 
3.2.2 TMPA reduces intrinsic effector caspase 9 activation, but has 
no impact on mitochondrial outer membrane potential 
The pro-apoptotic function of Nur77 has been reported to depend on its intracellular 
localization. Several studies described nuclear-cytoplasmic translocation of Nur77 in colon 
and gastric cancer cells as a prerequisite for apoptosis induction. This translocation was 
accompanied by association to BH3 and BH4 containing Bcl-2 family members following 
conformational change that induced mitochondrial depolarization and subsequent 
cytochrome-C release and caspase 9 activation115,143,174,175.  
To test, whether TMPA impacted on mitochondrial outer membrane permeabilization 
(MOMP) and effector caspase activation in re-stimulated primary human T-cells, MOMP was 
visualized during T-cell RICD using the mitochondrial membrane potential dependent 
fluorescent dye TMRE and flow-cytometric analysis (Figure 5). 
TMRE staining of primary human T-cell blasts revealed high fluorescence signal in non-re-
stimulated cells. PMA- and TCR crosslinking induced T-cell RICD was associated with 
reduced TMRE fluorescence, indicating MOMP and apoptosis induction (see Figure 2). FAS 
crosslinking was also associated with MOMP, implying that T-cell apoptosis per se is 
associated with MOMP. Unexpectedly, TMPA, applied at concentrations at 10µM or 50µM, 
did not alter MOMP, while it reduced T-cell RICD (Figure 5a). This lack of impacting on 
MOMP was observed regardless whether the percentage of TMRElo T-cells or the TMRE 
mean fluorescence intensity (MFI) was monitored (Figure 5a).  
Assessment of effector caspase 8 and 9 activation four hours after re-stimulation with titrated 
PMA concentrations revealed a dose-dependent increase of caspase 9 activation. PMA re-
stimulation also led to activation of caspase 8, although caspase 8 activation numerically was 
lower compared to activation of caspase 9 (Figure 5b). TMPA reduced PMA induced 
caspase 9 activity up to 40% compared to TMPA non-treated, re-stimulated T-cells blasts 
(Figure 5b). 
Taken together, TMPA reduced RICD in primary human T-cells. While this was associated 
with reduced activation of caspase 9, MOMP was insensitive to presence vs. absence of 
TMPA. 
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Figure 5 Effect of TMPA on MOMP and activation of effector caspases 
a) Primary human T-cell blasts (N=3) were re-stimulated with PMA, treated with agonistic anti-CD3 
monoclonal antibody (clone OKT3), agonistic FAS-specific monoclonal antibody (aFAS) or left 
unstimulated in medium. TMPA was added at the indicated concentrations prior to re-stimulation. Four 
hours later, CD3+CD8+ T-cells were assessed for apoptosis using annexinV staining and flow-
cytometric analysis according to 2.3.3. For assessment of the mitochondrial potential, the same T-cell 
blasts were incubated after four hours of re-stimulation for additional 30 minutes at 37°C in medium 
containing TMRE according to the manufacturers protocol (Immunochemistry technologies). TMRE 
fluorescence was measured by flow-cytometry. b) For assessment of caspase activation, primary 
human T-cell blasts (N=2) were incubated after four hours of re-stimulation with titrated amounts of 
PMA for additional 30 minutes at 37°C in medium containing fluorochrome-labeled caspase 8- or 
caspase 9-specific inhibitors according to the manufacturers protocol (Immunochemistry technologies) 
before flow-cytometric analysis. The percentage of T-cell blasts displaying activated caspases is 
depicted. 
For flow-cytometric analysis, cells were gated on CD3+/CD8+. Statistics were done with two-way-
ANOVA test, ns indicates non-significant changes, * = p<0,05, ** = p<0,01, *** = p<0,001. Mean and 
standard deviation are shown. 
 
3.2.3 TMPA does not affect effector functions of primary human T-
cell blasts 
Following the observation, that TMPA significantly blocked RICD in primary human T-cells, 
we next tested whether TMPA altered T-cell effector function. Four hours after re-stimulation 
of human T-cell blasts with PMA or agonistic anti-CD3 antibody, cells were analyzed for 
intracellular content of TNFa and IFNɣ. While PMA and anti-CD3 rapidly induced TNFa and 
IFNɣ, presence vs. absence of TMPA did not significantly alter the production of both effector 
cytokines, although a trend to lower cytokine production was observed with high-dose TMPA 
(50µM) (Figure 6). 
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Figure 6 Effect of TMPA on primary human T-cell blast effector function  
To assess the effect of TMPA on T-cell blast intrinsic effector functions, primary human T-cell blasts 
(N=3) were re-stimulated with PMA, treated with agonistic anti-CD3 monoclonal antibody (clone 
OKT3), agonistic FAS-specific monoclonal antibody (aFAS) or left unstimulated in medium. TMPA was 
added at the indicated concentrations as was Brefeldin-A (5 µg/ml) to block cytokine secretion. After 
four hours of re-stimulation, flow-cytometric analysis of TNFa or IFNγ expression was performed 
following intra-cellular cytokine staining according to 2.3.4. Cells were gated for CD3+/CD8+ for flow-
cytometric analysis. Statistics were performed using a two-way-ANOVA test, ns indicates non-
significant changes, * = p<0,05, ** = p<0,01, *** = p<0,001. Mean and standard deviation are shown. 
 
3.2.4 Primary human T-cell proliferation in the presence of Nur77 
binding small molecule compounds 
As TMPA consistently reduced human T-cell RICD, we next tested the effect of TMPA on 
primary T-cell proliferation (Figure 7).  
Peripheral blood mononuclear cells (PBMC) were activated with agonistic antibodies against 
CD3 and CD28 in the presence of IL-2 to induce T-cell expansion. T-cell proliferation was 
monitored by flow-cytometric tracking of CFSE fluorescence signal loss following T-cell 
division. Four days after primary stimulation, T-cells showed decreased CFSE fluorescence 
indicative of functional cell division. TMPA and THPN at low doses (TMPA 10µM, THPN 
1µM) revealed no detectable impact on cell division, whereas high doses (TMPA 50µM, 
THPN 10µM) were associated with inhibition of primary T-cell proliferation (Figure 7a).  
In a confirmatory experiment, primary T-cell expansion was induced by phytohemagglutinin 
(PHA) in the presence or absence of IL-2. T-cell activation using anti-CD3/CD28 monoclonal 
antibodies served as control. Cells were cultured in the presence or absence of 10µM TMPA. 
T-cell intrinsic CFSE signal was monitored by flow-cytometry over the next four following 
days. PHA, similar to activation by anti CD3/CD28 antibodies, led to CFSE dilution indicative 
of intact T-cell division. TMPA at the concentrations of 10µM did not affect primary T-cell 
division (Figure 7b). 
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To test whether constant presence of TMPA during primary T-cell proliferation impaired its 
effect to reduce RICD (tachyphylaxis), primary T-cells were expanded following PHA 
stimulation in the presence of IL-2 for seven days. TMPA was added before primary 
stimulation and every three days (together with fresh IL-2) at a concentration of 10µM. T-
cells stimulated in the absence of TMPA served as control. Seven days later, RICD was 
induced by titrated amounts of PMA, again in the presence vs. absence of 10µM TMPA. 
Independent whether T-cell blasts were expanded in the presence or absence of TMPA, 
TMPA reduced T-cell intrinsic RICD during the four hours of re-stimulation (Figure 7c). In 
other words, we do not have experimental evidence that constant encounter with TMPA 
leads to tachyphylaxis regarding its potential to reduce T-cell RICD. 
 
Figure 7 Effect of TMPA and THPN on primary T-cell proliferation 
a), b) PBMC were CFSE-labeled according to 2.2.3 (N=2). PBMC derived T-cells were subsequently 
activated with agonistic monoclonal antibodies against CD3/CD28 or PHA plus IL-2. Non-stimulated 
conditions served as control. TMPA and THPN were added at the indicated concentrations prior to 
stimulation. Dilution of CFSE fluorescence as an indicator of cell division was monitored by flow-
cytometry after four days (a) or at the indicated time points after activation (b). All cells were stained 
for CD3 and CD8 expression and flow-cytometrically gated on CD3+/CD8+ for analysis. c) To analyze 
whether presence vs. absence of TMPA during primary T-cell proliferation impacted on its effect 
during T-cell RICD, primary human T-cell blasts (N=2) were expanded using PHA plus IL-2 for seven 
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days in RPMI medium containing or not containing TMPA (10 µM). TMPA was freshly added together 
with fresh IL-2 after three days of culture. After seven days of primary T-cell expansion, T-cell blasts 
were re-stimulated using the indicated titrated concentrations of PMA or were left unstimulated, again 
in the presence vs. absence of TMPA (10 µM). Four hours later, T-cell RICD was measured by 
annexinV staining and flow-cytometric analysis according to 2.3.3. All cells were gated on CD3+/CD8+ 
for analysis. Results of individual experiments are shown. 
 
3.3 TMPA reduces TCR mediated RICD in primary murine T-cell 
blasts 
Having shown TMPA to consistently impact on RICD in primary human T-cell blasts, we 
wanted to test, whether TMPA is also capable of reducing RICD in murine primary T-cells. 
Therefore, we used TMPA in the context of T-cells isolated from 327tg mice. Almost all CD8+ 
T-cells derived from 327tg mice express a transgenic TCR specific for the immunodominant 
LCMV peptide gp33-41164–166. These transgenic T-cells allowed us to analyze the function of 
TMPA in the context of RICD induced by crosslinking the TCR by re-stimulation with the 
cognate peptide (Figure 8). 
LCMV-specific CD8+ T-cells were first expanded by in vitro incubation with gp33-41 peptide 
in the presence of IL-2. Eight days later, RICD was induced by re-application of gp33-41 and 
T-cell apoptosis was assessed by annexinV staining and flow-cytometric analysis four hours 
later. Unspecific re-stimulation using the ovalbumin derived OVA peptide served as a control 
and did not result in RICD (Figure 8a). TMPA reduced murine T-cell RICD dose-dependently 
with a similar dose response curve as observed in primary human T-cell RICD (Figure 8a). 
gp33-41 re-stimulation led to TNFa and IFNɣ production in more than 60% of the LCMV-
specific T-cell blasts (Figure 8b). OVA re-stimulation as a control did not induce cytokine-
production in LCMV-specific T-cells. As observed in human primary T-cell blasts, TMPA did 
not significantly impair cytokine production upon re-stimulation, although a tendency to 
reduced IFNɣ production was observed at a TMPA concentration of 50µM (Figure 8b). In 
line with human T-cell blasts, TMPA was not associated with increased T-cell death under 
non-re-stimulated conditions (Figure 8b). 
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Figure 8 Effect of TMPA on murine T-cell RICD and murine T-cell blast effector 
functions 
a), b) Splenocyte-derived LCMV-specific primary murine T-cell blasts (N=4) were generated using 
327tg mice that contain TCR-transgenic CD8+ T-cells specific for the immunodominant LCMV-
glycoprotein-derived gp33-41 peptide according to 2.1.4. Eight days after initial T-cell expansion using 
gp33-41 and IL-2, murine T-cell blasts were in vitro re-stimulated using gp33-41, ovalbumin-derived 
OVA peptide or were left unstimulated. TMPA was added at the indicated titrated concentrations prior 
to re-stimulation. (a) Four hours later, T-cell RICD was measured by annexinV staining and flow-
cytometric analysis according to 2.3.3. (b) T-cell intrinsic production of TNFa and Interferonɣ (IFNɣ) 
was assessed by intracellular cytokine staining and flow-cytometric analysis. Brefeldin-A (5 µg/ml) was 
used to block cytokine secretion during the re-stimulation cultures.  
All cells were gated on CD3+ for flow-cytometric analysis. Statistics were done with two-way-ANOVA 
test, ns indicates non-significant changes, * = p<0,05, ** = p<0,01, *** = p<0,001. Mean and standard 
deviation are shown. 
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3.4 Analysis of T-cell RICD associated transcriptomes in the 
presence vs. absence of TMPA 
Our previous experiments substantiated the function of Nur77 binding small molecule 
compounds to reduce T-cell intrinsic RICD in both murine and human T-cell blasts. To gain 
insight into how TMPA might mechanistically regulate T-cell RICD, we performed RNA 
sequencing experiments (Figure 9). 
3.4.1 Identification of a distinct differentially regulated, TMPA 
sensitive small set of genes in re-stimulated primary T-cells 
For RNA sequencing, splenocyte derived T-cell blasts from four 327tg mice were first 
expanded and subsequently re-stimulated with gp33-41 peptide. Processing of individual 
mice, T-cell expansion and RICD induction was performed individually to augment statistical 
power. To also get information on dose-dependent TMPA effects on gene transcription 
during T-cell RICD, RNA sequencing was performed on murine T-cell blasts re-stimulated in 
the presence of 5µM and 50µM TMPA, respectively. Besides non-re-stimulated T-cell blasts, 
unspecific re-stimulation with OVA peptide served as an additional control. As OVA re-
stimulated T-cell blasts did not reveal significant differences in mRNA regulation compared to 
non-re-stimulated cells, non-stimulated (NS) and OVA stimulated (OVA) conditions could be 
merged and used as a combined control throughout the analysis of the RNA sequencing 
data. This generated a higher statistical power for the definition of significant TMPA related 
changes in gene regulation during T-cell RICD.  
Clustering analysis of all samples demonstrated, that the generated dataset was valid and 
robust, as the samples showed low differential gene regulation within the re-stimulated and 
the control conditions, respectively. Also, no major differences regarding gene transcription 
between individual mice were observed, whereas comparison of gp33-41 re-stimulated with 
non-re-stimulated conditions revealed major differential gene regulation (Figure 9a). 
Principal component analysis of the generated data set showed, that the majority of the 
differential gene regulation (94,47% - principal component x) emerged from TCR crosslinking 
induced re-stimulation, indicating a (expected) major gene regulation due to re-stimulation 
itself. However, presence vs. absence of TMPA in re-stimulated samples also revealed a 
dominant parameter for differential gene regulation (3,9% - principal component y). Plotting 
of both principal component parameters x and y demonstrated, that the gp33-41 re-
stimulated samples cluster together. Within re-stimulated T-cell blasts, TMPA treated vs. 
non-treated samples cluster separately together, visualizing a distinct impact of TMPA 
treatment on gene regulation in LCMV-specific re-stimulated primary T-cells blasts (Figure 
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9b). A TMPA related dose dependency could not be observed with this kind of analysis 
(Figure 9b). 
A detailed analysis of TMPA-related differential gene regulation by comparing RNA profiles in 
gp33-41 re-stimulated samples was performed. Statistical cutoffs were defined to evaluate 
the most significant regulated genes in the datasets. A stringent cutoff with a corrected p-
value (FDR) below 0,0005 and a log2 fold change (log2 FC) higher than 2,5 or lower than -2,5 
was applied. This evaluation revealed a gene set of 41 genes that were differentially 
regulated during gp33-41 peptide re-stimulation in a TMPA-dependent manner. Notably, 4 of 
these 41 genes belonged to the gene family encoding for proteins of the Slam receptor 
signaling axis (Figure 9c). One of these gene products, SAP is associated with x-linked 
lymphoproliferative disease (XLP). XLP is caused by loss of function (LOF) mutations in the 
SH2D1A gene, encoding for SAP176,177. It is noteworthy, that SAP deficiency has been 
reported to reduce RICD in human T-cell blasts66 comparable to what was observed during 
RICD in the presence of TMPA and THPN treatment. Therefore, the observed TMPA-
dependent regulation of Sh2d1a / SAP during T-cell RICD got into our focus of subsequent 
experimental studies. 
Results 
Florian Marquardsen                                                                                      Immunodeficiency 37
 
Figure 9 Effect of TMPA on mRNA regulation during T-cell RICD 
(a-c) Splenocyte-derived LCMV-specific primary murine T-cell blasts (N=4) were generated from 327tg 
mice that contain transgenic CD8+ T-cells specific for the immunodominant LCMV-glycoprotein-
derived gp33-41 peptide according to 2.1.4. Eight days following initial T-cell expansion using gp33-41 
peptide plus IL-2, murine T-cell blasts were in vitro re-stimulated using gp33-41, ovalbumin-derived 
OVA peptide or left unstimulated in medium. TMPA was added at the indicated final concentrations 
prior to re-stimulation. Four hours later, T-cell blasts were either assessed for T-cell RICD with 
annexinV staining and flow-cytometric analysis according to 2.3.3 or replicates of the same T-cell 
blasts were lysed for subsequent RNA sequencing with special lysis buffer (Machery-Nagel). a) A 
heatmap of all sequenced samples in a cluster analysis regarding transcriptional regulation is 
depicted. Non-re-stimulated (NS) and non-specifically peptide re-stimulated (OVA) samples were 
merged, since transcriptional regulation of these two control groups did not statistically differ (data not 
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shown). Every sample is compared with each other and attributed with a differential gene regulation 
score between 0,5 (high differential gene regulation) and 1 (low differential gene regulation). 
b) Principal component analysis of all sequenced samples is depicted. Principal component parameter 
1 (PC1, x-axis, re-stimulation) explains 94,47% of all differential regulated genes. Principal component 
2 (PC2, y-axis, TMPA treatment) explains 3.9 % of all differential regulated genes. RNA sequencing 
data revealed clustering of re-stimulated non-TMPA treated (red dots) samples vs. re-stimulated 
TMPA treated samples (blue and green dots) regarding differential gene regulation. 
c) T-cell blasts were either monitored for RICD using annexinV staining and flow-cytometry according 
to 2.3.3 or cells were lysed four hours after re-stimulation and RNA sequencing was performed (see 
2.5). Highly differential regulated genes in re-stimulated TMPA-treated vs. re-stimulated non-TMPA 
treated samples are depicted. Genes belonging to the Slam receptor signaling axis are highlighted in 
purple. 
Statistics were performed using two-way-ANOVA test, ns indicates non-significant changes, * = 
p<0,05, ** = p<0,01, *** = p<0,001. Mean and standard deviation are shown. 
 
3.4.2 TMPA-dependent regulation of Sh2d1a / SAP during RICD in 
primary murine and human T-cell blasts 
Log2 relative expression of Sh2d1a in murine LCMV-specific T-cell blasts that were analyzed 
for the RNA sequencing experiments are depicted in Figure 10a. Sh2d1a mRNA was 
expressed constitutively in non-re-stimulated T-cell blasts (NS) and unspecific (OVA) peptide 
re-stimulated T-cell blasts. Re-stimulation of LCMV-specific T-cell blasts with cognate gp33-
41 peptide did not change Sh2d1a mRNA expression, while gp33-41 peptide re-stimulation 
in the presence of TMPA (both, low (5µM) and high dose (50µM)) led to profound reduction 
of Sh2d1a mRNA expression (Figure 10a). Further analyses in primary human T-cells were 
performed to test whether the regulation of SH2D1A and its gene product SAP by TMPA 
during T-cell RICD was consistent in different species (Figure 10). 
In keeping with the results in antigen-specific murine T-cell blasts, SH2D1A mRNA 
expression, as assessed by real-time PCR, was reduced during human T-cell RICD in a 
TMPA-dependent manner (Figure 10b). While SH2D1B1 and SLAMF6 mRNA showed no 
TMPA-dependent regulation during human T-cell RICD, SLAMF1 mRNA expression was 
significantly increased in the presence of TMPA during T-cell RICD (Figure 10b). Thus, the 
TMPA-dependent regulation of members of the SLAM receptor signaling axis observed 
during RICD of LCMV-specific transgenic murine T-cell blasts was experimentally 
recapitulated in primary human T-cell RICD. 
Consistent with SH2D1A mRNA regulation during human T-cell RICD, SAP protein was 
downregulated in a TMPA-dependent manner during primary human T-cell RICD within four 
hours (Figure 10c). As a control, apoptosis induction in human T-cell blasts by recombinant 
soluble FAS ligand (FASL) did not alter T-cell intrinsic SAP expression independently of 
TMPA treatment. Isotype control antibody confirmed specificity of the flow-cytometric 
quantification of SAP (Figure 10c). In summary, Sh2d1a/SH2D1A mRNA and SAP protein 
appeared to be downregulated during T-cell RICD in a TMPA-dependent manner.. 
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Figure 10 Effect of TMPA on Sh2d1a mRNA / SAP protein levels during T-cell RICD 
a) RNA sequencing raw data were analyzed for Log2 relative expression of Sh2d1a (gene encoding 
for SAP) in all indicated 9 re-stimulation conditions (N=4) (see Figure 9) using an in-house analysis 
tool (bioinformatics core facility of the Department of Biomedicine Basel). For re-stimulation, 
splenocyte derived primary murine LCMV-specific T-cell blasts were re-stimulated using LCMV 
peptide gp33-41, ovalbumin-derived OVA peptide or were left unstimulated. TMPA was directly added 
at the indicated concentrations prior to re-stimulation. RNA was isolated after four hours of re-
stimulation. b) Primary human T-cell blasts (N=4) were re-stimulated with agonistic anti CD3-specific 
monoclonal antibody (clone: OKT3) or left unstimulated in medium in the presence vs. absence of 
TMPA (10 µM). mRNA expression of SH2D1A, SH2D1B1, SLAMF1 and SLAMF6 was assessed by 
quantitative PCR after four hours of re-stimulation according to 2.4.3. All mRNA expression values are 
normalized to housekeeping genes 18s and Ipo8. The depicted fold change values are normalized to 
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mRNA expression in non-stimulated conditions. c) Primary human T-cell blasts (N=4) were in vitro re-
stimulated with PMA, treated with soluble recombinant FASL or were left unstimulated in presence vs. 
absence of TMPA (10 µM). SAP expression was measured using intracellular-staining and flow-
cytometric analysis four hours after re-stimulation according to 2.3.4. IgG1 𝜅 isotype control was used 
as an isotype control. Individual MFI values are depicted. Mean and standard deviation are shown. 
Statistics were performed using two-way-ANOVA test, ns indicates non-significant changes, * = 
p<0,05, ** = p<0,005, *** = p<0,0005. Mean and standard deviation are shown. 
 
3.5 Effect of TMPA on T-cell RICD and T-cell effector functions 
in Nur77 deficient T-cells 
Experiments in both primary human and murine T-cells demonstrated a consistent 
impairment of RICD in the presence of the Nur77 binding small molecule TMPA. Since these 
compounds had been demonstrated to induce apoptosis in various cancer cell lines94,95 and 
hepatocytes96, we next assessed whether the observed apoptosis inhibiting effect by these 
Nur77 binding compounds in T-cells was depending on Nur77 expression. For this purpose, 
Nur77 deficient Nr4a1-/- mice81,148,154 were crossed to 327tg mice. This allowed us to 
experimentally address the question, whether TMPA related impairment of T-cell RICD 
required Nur77 protein (Figure 11). 
3.5.1 TMPA reduces T-cell RICD Nur77-independently 
Log2 relative expression of all 3 NR4A members Nr4a1, Nr4a2 and Nr4a3 from the RNA 
sequencing datasets of re-stimulated primary murine T-cell blasts confirmed rapid, early 
mRNA induction of Nr4a1, encoding for Nur77. The other two NR4A gene family members 
Nr4a2 and Nr4a3 encoding for Nurr1 and Nor1, respectively, were also rapidly induced 
during murine T-cell RICD (Figure 11a).  
We next expanded LCMV-specific T-cell blasts that were either Nur77 deficient or Nur77 
competent using splenocytes from either 327tgxNur77-/- or 327tgxNur77+/- or 327tgxNur77+/+ 
mice. Flow-cytometric analysis two hours following re-stimulation with gp33-41-peptide 
demonstrated that Nur77 upregulation was similar in Nur77+/- vs. Nur77+/+ T-cell blasts, 
whereas Nur77 was indeed absent in Nur77-/- T-cell blasts (Figure 11b). 
Assessment of T-cell RICD by annexinV staining and flow-cytometric analysis four hours 
after gp33-41 peptide re-stimulation demonstrated RICD in approximately 60% of LCMV-
specific T-cell blasts, regardless of Nur77 competence (Figure 11c). Non-re-stimulated T-cell 
blasts served as control and demonstrated absence of RICD. TMPA was associated with a 
significant and dose-dependent reduction of RICD, both in Nur77 competent but also 
similarly in Nur77 deficient T-cell blasts (Figure 11c). Together, this experimental evidence 
implicated that Nur77 expression is not required for the RICD inhibiting effect of TMPA in 
primary murine T-cell blasts (Figure 11c). In addition to the flow-cytometric assessment of 
Results 
Florian Marquardsen                                                                                      Immunodeficiency 41
Nur77, we also measured Nr4a1 and Nr4a3 mRNA induction during Nur77 competent vs. 
Nur77 deficient T-cell RICD by real-time PCR. Consistent with flow-cytometric assessment of 
Nur77 expression, re-stimulation of LCMV-specific T-cell blasts with gp33-41 peptide 
revealed strong induction of Nr4a1 in Nur77 competent T-cells (3000 fold increase), but not 
in Nur77 deficient T-cells. Following T-cell blast re-stimulation, also Nr4a3 mRNA expression 
was highly induced, notably with a non-significant trend to augmented induction in Nur77 
deficient T-cell blasts (Figure 11d). Thus, while Nur77 was not required for the RICD 
inhibiting properties of TMPA, we cannot exclude that in the absence of Nur77, upregulation 
of other NR4A family members might have functionally compensated for absent Nur77. 
3.5.2 RICD associated T-cell effector functions are sustained by 
TMPA independently of Nur77 expression 
To test, whether TMPA impacted on T-cell effector function during murine T-cell RICD, and 
whether this occurred Nur77-dependently, Nur77 competent vs. deficient LCMV-specific T-
cell blasts were assessed for TNFa and IFNɣ production four hours after in vitro re-
stimulation with gp33-41 peptide. TNFa as well as IFNɣ were rapidly induced in re-stimulated 
LCMV-specific T-cell blasts regardless of Nur77 expression (Figure 11e). TMPA treatment 
with low dose (10µM) did not affect cytokine production, whereas high dose (50µM) TMPA 
was associated with non-significantly reduced T-cell intrinsic cytokine production (Figure 
11e). 
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Figure 11 Effect of TMPA on T-cell RICD and T-cell effector functions in Nur77 
competent vs. deficient T-cells 
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a) RNA sequencing raw data were analyzed for Log2 relative expression of Nr4a1, Nr4a2 and Nr4a3 
(genes encoding for Nur77, Nurr1 and Nor1) in all indicated 9 re-stimulation conditions (N=4) (see 
Figure 9). b-e) Murine CD8+ T-cell blasts specific for the LCMV-peptide gp33-41, either Nur77 
competent of Nur77 deficient, were generated using splenocytes from 327tgxNur77-/- mice (N=3) and 
from 327tgxNur77+/- or 327tgxNur77+/+ (N=3) mice and stimulation with gp33-41 peptide plus IL-2. b) 
Fourteen days later, Nur77 expression was assessed by flow-cytometry following re-stimulation with 
gp33-41 for two hours. Non-stimulated T-cell blasts served as control. Flow cytometry was performed 
according to 2.3.4. c) Sixteen days following initial stimulation, LCMV-specific T-cell blasts were in 
vitro re-stimulated with the LCMV-derived peptide gp33-41 or left unstimulated in the presence vs. 
absence of the indicated concentration of TMPA prior to re-stimulation. Apoptosis was measured by 
annexinV staining and flow-cytometric analysis according to 2.3.3. four hours after re-stimulation d) 
Sixteen days following generation of T-cell blasts, cells were re-stimulated using gp33-41 (1 nM) or left 
unstimulated. Four hours later, mRNA expression levels of Nr4a1 and Nr4a3 were measured by 
quantitative PCR according to 2.4.3. All mRNA expression values are normalized to housekeeping 
genes 18s and Ipo8. Fold change values normalized to non-re-stimulated conditions are depicted. e) 
Eighteen days following generation of LCMV-specific T-cell blasts, T-cell RICD was induced using 
LCMV-derived peptide gp33-41 (1 nM) or T-cell blasts were left unstimulated in the presence vs. 
absence of the indicated concentration of TMPA. Four hours later, T-cell intrinsic production of TNFa 
and Interferonγ (IFNγ) was assessed by intracellular cytokine staining and flow-cytometric analysis. 
Brefeldin-A (5 µg/ml) was used during the four hours of re-stimulation to prevent cytokine secretion.  
Statistics were performed using two-way-ANOVA test, ns indicates non-significant changes, * = 
p<0,05, ** = p<0,01, *** = p<0,001. Mean and standard deviation are shown. 
 
3.5.3 TMPA impairs RICD Nur77-independently in primary human T-
cells 
To test, whether the observed Nur77 independence of the TMPA mediated impairment of 
murine T-cell RICD was consistently observed in human T-cell RICD, Nur77 expression was 
knocked down by transfection of human T-cell blasts with NR4A1-specific vs. non-specific 
siRNA (Figure 12). 24 hours after transfection, T-cell blasts were enriched for live cells using 
a magnetic bead based dead-cell removal procedure (see methods). Re-stimulation by TCR 
crosslinking with an agonistic anti-CD3 antibody induced RICD in 60% of T-cell blasts 
independently of Nur77 siRNA knock-down. Flow cytometric assessment two hours following 
re-stimulation demonstrated almost complete abrogation of Nur77 protein expression in 
Nur77-specific siRNA treated T-cell blasts (Figure 12). Thus, Nur77-independence of the 
TMPA regulated RICD was experimentally shown both in primary murine and primary human 
T-cell blasts. 
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Figure 12 Effect of TMPA on RICD in Nur77 competent vs. deficient primary human T-
cell blasts 
Primary human T-cells blasts (N=5) were transfected by electroporation with NR4A1-specific siRNA or 
non-specific siRNA according to 2.2.2. T-cell blasts were then rested for 24 hours and subsequently 
enriched for live cells using a magnetic bead-based dead cell removal procedure according to the 
manufacturer’s protocol. Subsequently, T-cell blasts were in vitro re-stimulated with PMA or left 
unstimulated in the presence vs. absence of TMPA (10 µM). Four hours later, apoptosis was 
monitored using annexinV staining and flow-cytometric analysis according to 2.3.4 Quantification of 
apoptosis in all 5 individual T-cell blast samples is depicted.  
To control for Nur77 protein knock-down efficiency, Nur77 expression was assessed two hours after 
PMA triggered re-stimulation using flow-cytometry. Flow-cytometric Nur77 staining of non-re-
stimulated T-cell blasts served as a control. Histograms from one representative experiment are 
depicted. A summary graph shows the TMPA driven reduction of T-cell RICD in Nur77 competent vs. 
Nur77 deficient primary human T-cell blasts (mean of N=5 is depicted). 
For flow-cytometric analysis, all cells were gated on CD3+/CD8+. Statistics were done with two-way-
ANOVA test, ns indicates non-significant changes, * = p<0,05, ** = p<0,01, *** = p<0,001. Mean and 
standard deviation are shown. 
 
3.6 Nur77-dependent down-regulation of Sh2d1a mRNA during 
T-cell RICD by TMPA 
RNA sequencing in re-stimulated LCMV-specific T-cell blasts demonstrated TMPA-
dependent Sh2d1a down-regulation (Figure 10). TMPA-dependent Sh2d1a down-regulation 
was confirmed during human T-cell RICD.  
To test, whether TMPA mediated, RICD associated Sh2d1a down-regulation occurs Nur77-
dependently, Sh2d1a mRNA expression was assessed by quantitative PCR during RICD of 
Nur77 competent vs. deficient murine LCMV-specific T-cell blasts (Figure 13). Sh2d1a 
mRNA was constitutively expressed in non-re-stimulated T-cell blasts regardless of Nur77 
expression. Re-stimulation with gp33-41 peptide in the absence of TMPA did not affect 
NS
OK
T3
OK
T3
 + 
TM
PA
 10
uM
0
10
20
30
40
Data 1
Ctrl
Nur77
Nur77
SS
C
Nonspecific siRNA
Nur77 siRNA
NS PMA
-60 -40 -20 0 20
% Reduction of RICD 
NS aCD
3
aCD
3 +
 TM
PA
An
ne
xin
+  (
%
)
*
Nur77 high
1,2 % 13 %
38 %0,9 %
*
10
30
20
40
Figure 12
Ctrl siRNA
Nur77 siRNA
-60 -40 -20 0 20
D2 Nur77 siRNA
D2 nonspecific siRNA
D1 Nur77 siRNA
D1 nonspecific siRNA
change in %
Nonspecific siRNA
Nur77 specific siRNA
Results 
Florian Marquardsen                                                                                      Immunodeficiency 45
Sh2d1a mRNA expression (Figure 13). In contrast, TMPA at low dose (10µM) and high dose 
(50µM) decreased mRNA expression of Sh2d1a by 50% in a Nur77-dependent manner 
(Figure 13). As a control, TMPA did not alter Sh2d1a mRNA expression in non-re-
stimulated, both Nur77 competent and -deficient T-cells (Figure 13).  
These results implied that in contrast to the TMPA-dependent impairment of T-cell RICD, the 
TMPA associated reduction of Sh2d1a mRNA expression during T-cell RICD required 
expression of Nur77 and could not be compensated by other NR4A family members. 
 
Figure 13 Effect of TMPA on Sh2d1a mRNA expression during RICD in Nur77 
competent vs. deficient primary murine T-cell blasts 
Splenocyte-derived LCMV-specific primary murine T-cell blasts were generated from Nur77 deficient 
327tgxNur77-/- mice (N=3) and from Nur77 competent 327tgxNur77+/- or 327tgxNur77+/+ (N=3) mice by 
stimulation with LCMV-derived gp33-41 peptide (1nM) plus IL-2 according to 2.1.4. 
Eight days later, LCMV-specific T-cell blasts were re-stimulated with LCMV gp33-41 peptide or left 
unstimulated in the presence vs. absence of TMPA at the indicated concentrations. Four hours later, 
Sh2d1a mRNA expression levels were measured by quantitative PCR. mRNA expression values are 
normalized to the housekeeping genes 18s and Ipo8. The depicted fold change values are normalized 
to RNA levels measured in non-re-stimulated T-cell blasts.  
Statistics were performed with two-way-ANOVA test, ns indicates non-significant changes, * = p<0,05, 
** = p<0,01, *** = p<0,001. Mean and standard deviation are shown. 
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4 Discussion 
Biological roles of Nur77 have been extensively experimentally addressed in various cell 
contexts in vitro and in vivo. Currently, NCBI search using the terms “Nur77” and “NR4A1” 
yield 1161 and 1121 results, respectively. In my PhD thesis we have Nur77 related functions 
during RICD of primary mature T-cells and have analyzed effects of pharmacological 
modulation of Nur77. To our knowledge, this is the first work demonstrating that 
pharmacological targeting of Nur77 decreases RICD in primary mature murine and human T-
cells. This finding reveals a high potential of these Nur77 targeting compounds or 
pharmacological derivatives to be used to treat diseases linked to dysregulated T-cell 
apoptosis. 
4.1 Nur77 regulates apoptosis via different mechanisms 
depending on the cellular context. 
The nuclear orphan receptor Nur77 was initially discovered as an early induced gene in 
response to serum- or nerve growth factor (NGF) in a pheochromocytoma rat cell line 
PC12178,179. Despite early discovery, that rapid induction of Nur77 is associated with 
apoptosis in T-cell hybridomas 82,145, the underlying mechanisms remained controversial. 
Structural analysis of Nur77 revealed a composition similar to other nuclear receptors such 
as the nuclear steroid receptor79. Accordingly, Nur77 contains three main functional domains, 
consisting of a DNA binding domain (DBD) regulating gene transcription, a transactivation 
domain (AF-1) and an atypical ligand binding domain (LBD) attributing Nur77 a special role 
among the nuclear receptors. The rather unusual accumulation of tightly packed hydrophobic 
residues inside the Nur77-LBD argued against the dependency on natural occurring ligands 
and proposed Nur77 to act as a ligand-independent constitutively active transcription 
factor180,181 A high degree of homology can be observed when analyzing the 3 members of 
the NR4A family, suggesting certain functional redundancy. This is in keeping with the 
finding, that while thymocytes from transgenic mice overexpressing a dominant negative 
form of Nur77 were protected from activation induced cell death146, Nur77 deficient mice 
showed no alteration of TCR induced apoptosis suggesting functional compensation through 
Nurr1 and/or Nor181. Consistently, our results demonstrate an unimpaired T-cell RICD in 
Nur77 deficient mature murine T-cells. Similarly, siRNA mediated knockdown of Nur77 
argued against a unique requirement of Nur77 during mature human T-cell RICD. 
The various pro-apoptotic mechanisms of Nur77 have been extensively investigated in 
cancer research156,182,183. Beside the initial discovery of Nur77 to promote cancer cell 
apoptosis via transcriptional gene induction in solid tumor cell lines, other experimental 
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evidence proposed Nur77 to promote apoptosis via posttranscriptional modifications like 
phosphorylation or SUMOylation87,161,184,185 and via non-genomic trans-repression 
mechanisms by binding to and inactivating anti-apoptotic Bcl-2 protein family members 
following nuclear export140,143,150,161,182,185,186. Several studies suggested fundamental 
differences of Nur77 driven functions in immature vs. mature T-cells. Whereas Nur77 
induction promoted clonal deletion during negative selection of thymocytes, it was found to 
drive proliferation and survival in mature, peripheral T-cells25,86,144,151,187. 
In mature, re-stimulated T-cell blasts, our results demonstrate rapid Nur77 up-regulation 
during RICD. In line with the findings of Cunningham and colleagues25,151, we did not find 
experimental evidence of Nur77 nuclear export during re-stimulation of both primary murine 
and human T-cell blasts using a recently developed device that combines flow-cytometric 
analysis with fluorescence microscopy and brightfield imaging (Image Stream X®, Merck 
Milipore, data not shown). Future studies using T-cell adapted nuclear vs. cytosolic 
fractionation methods and western-blot analysis will allow to study whether Nur77 nuclear 
export occurs during mature T-cell RICD and may elucidate its relevance. 
4.2 Modulation of T-cell RICD by Nur77 binding small molecule 
compounds 
The apoptosis-related functions of Nur77 revealed a high potential for being drug-targeted in 
cancer therapy. Since no natural occurring ligand of Nur77 has been described, several 
natural-occurring or synthetic small molecule compounds binding to the hydrophobic amino 
residues within the Nur77-LBD, have been described to alter the biology of cancer cells or 
hepatocytes in a Nur77-dependent manner93–96,162. Here we applied some of these 
compounds for the first time during primary expansion and RICD of mature T-cells. While 
cytosporone-B and THPN (1-(3,4,5-trihydroxyphenyl)nonan-1- one) were reported to induce 
apoptosis in tumor cell lines and in tumors in vivo via driving nuclear export of Nur77, TMPA 
(ethyl [2,3,4-trimethoxy-6-(i-octanoyl) phenyl]acetate) was shown to reduce blood glucose 
levels in diabetes-prone mice96. Its anti-tumor effects and its impact on Nur77-associated 
apoptosis and nuclear export have not been addressed yet. Application of these Nur77 
binding small molecules to mature primary T-cell blasts revealed a rather unexpected albeit 
consistent reduction of RICD, given that these compounds were reported to induce 
apoptosis. 
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4.2.1 Nur77 binding small molecule compounds impair TCR 
induced RICD in mature T-cells 
Our experiments demonstrated that human T-cell RICD occurred MEK/ERK-dependently. 
Reduced phosphatidylserine exposure following re-stimulation in the presence of MEK 
inhibitors correlated with reduced caspase 9 activation. In contrast to cancer cell lines and 
hepatocytes, T-cells do not show constitutive expression of Nur77. However, re-stimulation 
of mature T-cell blasts was followed by rapid Nur77 induction, which was prevented by MEK 
inhibition. Notably, we did not observe altered ERK phosphorylation during T-cell RICD in the 
presence of TMPA or THPN (data not shown) and rapid Nur77 upregulation during T-cell 
RICD was not affected by TMPA or THPN. Thus, the reduced T-cell RICD in the presence of 
TMPA and THPN could not be explained by altered MEK/ERK signaling. While T-cell RICD 
was reduced, T-cell intrinsic TNFa and IFNɣ production following in vitro re-stimulation were 
not significantly affected in both primary human and murine T-cell blasts by TMPA. Presence 
vs. absence of TMPA during primary human T-cell expansion did not affect its anti-apoptotic 
potential during T-cell re-stimulation. However, we observed reduced primary proliferation of 
mature T-cells in the presence of higher doses of TMPA and THPN. Nur77 is also rapidly 
upregulated during primary T-cell activation (data not shown), however we have not yet 
addressed whether the observed anti-proliferative effects of higher concentrations of TMPA 
or THPN occur Nur77-dependently. 
4.3 Dual function of TMPA in mature T-cell RICD 
Since we have observed counterintuitive anti-apoptotic effects of the Nur77 binding 
compounds THPN and TMPA on T-cell RICD, it was important to clarify, whether this effect 
was Nur77-dependent. Transcriptional profiling by RNA sequencing and analysis of RICD in 
Nur77 competent vs. deficient murine LCMV-specific T-cell blasts revealed both, Nur77-
dependent but also Nur77-independent effects of these small molecule compounds during T-
cell RICD. A graphical summary assembling Nur77-independent vs. dependent functions of 
Nur77-LBD binding compounds is depicted in Figure 14 and Figure 15. 
4.3.1 Nur77-independent impairment of T-cell RICD 
Nur77 has been consistently reported as inductor of cell death in various solid tumor types 
like colon-, gastric-, pancreatic-, breast- or lung tumors even with predictive survival 
correlation in vivo101,121,126,127,175. The anti-tumor function of Nur77 targeting small molecule 
compounds has been demonstrated to depend on direct binding to the Nur77 LBD. 
Our experimental data suggest a Nur77-independent T-cell RICD-reducing effect of these 
compounds (summarized in Figure 14). In line with the previously reported inconspicuous 
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phenotype of Nur77 deficient mice regarding activation induced T-cell apoptosis81,154, genetic 
absence of T-cell intrinsic Nur77 did not affect T-cell RICD in mature murine T-cell blasts. In 
addition, siRNA knockdown of Nur77 in mature human T-cell blasts did similarly also not 
affect T-cell RICD. Still, TMPA reduced T-cell RICD, however similarly in Nur77 competent 
vs. deficient T-cell blasts. A functional redundancy between NR4A family members regarding 
T-cell apoptosis has been reported, especially between the highly homologous proteins 
Nur77 and Nor1105,154. Our experimental evidence suggests the presence of a Nur77-
independent target for TMPA/THPN in mature T-cells undergoing RICD (Figure 14). Since 
we have demonstrated that Nor1 up-regulation is (non-significantly) augmented in Nur77 
deficient T-cell blasts, these findings would be consistent with functional redundancy 
between Nur77 and Nor1. However, preliminary experiments using a combined siRNA 
mediated knockdown of Nur77 plus Nor1 argued against a compensating role of Nor1 during 
human T-cell RICD in Nur77 deficient T-cell blasts (data not shown). An alternative 
hypothesis to explain our experimental data would be that Nur77 binding small molecules 
interact with other, NR4A family non-related proteins involved in apoptosis. This alternative 
hypothesis is experimentally supported by the evidence that TMPA did not alter MOMP 
during T-cell RICD while caspase 9 showed a reduced activity in the presence of TMPA. 
Preliminary experimental evidence in favor of the latter hypothesis is that TMPA inhibited 
primary T-cell apoptosis induced by the indolcarbazole staurosporine, which occurs in the 
absence of Nur77 and Nor1 induction (data not shown). A potential non-NR4A family target 
for TMPA, based on these experimental results, could be a direct inhibitor of activated 
caspase 9 such as XIAP188, a constitutively expressed anti-apoptotic regulator protein 
encoded by the BIRC4 gene. Further investigation will address whether TMPA alters XIAP 
expression during T-cell RICD and whether the anti-apoptotic effects of TMPA depend on 
XIAP expression (Figure 14). 
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Figure 14 Nur77-independent impact of TMPA on RICD in primary mature T-cells 
PS – phosphatidylserine, CytC – cytochrome C, MOMP – mitochondrial outer membrane 
permeabilization,           activating function,           inhibiting function,           gene induction 
4.3.2 Nur77-dependent regulation of Sh2d1a 
Very early studies of Nur77 in TCR-mediated apoptosis have reported a crucial role of Nur77 
transcription activity, that strictly correlated with its pro-apoptotic function, even in vivo187. In 
addition, overexpression and knockout systems of Nur77 in various solid tumor cell lines 
demonstrated consistent evidence of Nur77 to regulate apoptosis by de novo gene induction 
via its transcriptional activity101,120,175,189. Based on the experimental evidence of TMPA to 
reduce RICD in a Nur77-independent manner, we therefore compared transcriptional profiles 
during T-cell RICD in the presence vs. absence of TMPA. RNA sequencing using transgenic 
LCMV-specific murine T-cell blasts uncovered a set of 41 genes, that were significantly 
differentially regulated in a TMPA-dependent manner during T-cell RICD. Notably, 10% of 
these genes consisted of members of the Slamf receptor signaling axis, including the 
receptors Slamf1 (Slamf1), Slamf6 (Slamf6) and the intracellular adapter proteins SAP 
(Sh2d1a) and EAT2 (Sh2d1b1). SAP is an intracellular adapter protein of the costimulatory 
Slamf1- and Slamf6 receptor signaling axis, and is predominantly expressed in T- and 
natural killer (NK-) cells, whereas it is not expressed in B cells. Loss of function mutations in 
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the SAP encoding gene SH2D1A cause x-linked lymphoproliferative disease (XLP)176,177,190. 
In XLP patients, clinical phenotypes like severe infectious mononucleosis, 
lymphoproliferation and lymphoma as well as hypogammaglobulinemia are typically triggered 
by EBV infection, while no increased susceptibility against other pathogens has been 
reported. Importantly, RICD has been reported to be impaired in SAP deficient T-cells66 
similar to our results using TMPA in SAP competent T-cell blasts. 
Re-stimulation of Nur77 competent vs. deficient primary murine T-cell blasts demonstrated 
that the TMPA-dependent down-regulation of Sh2d1a mRNA during RICD occurred only in 
Nur77 competent cells and was obviously not compensated by Nor1 expression 
(summarized in Figure 15). 
 
Figure 15 Nur77-dependent impact of TMPA on RICD in primary mature T-cells 
          activating function,            inhibiting function,           gene induction 
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4.4 Potential clinical application of Nur77 binding small 
molecule compounds 
Our data demonstrate evidence for Nur77 binding small molecule compounds to reduce T-
cell RICD. These compounds, designed to specifically bind to the unique hydrophobic LBD of 
the constitutive active transcription factor Nur77, reduced T-cell RICD Nur77-independently 
and modified Sh2d1a transcription in a Nur77-dependent manner. 
The Nur77-independent molecular target of TMPA and THPN, respectively, remains to be 
defined. Our data suggest a target acting within the intrinsic apoptosis pathway downstream 
of the mitochondria, since MOMP was unaffected, whereas activation of caspase 9 was 
reduced in the presence of TMPA during T-cell RICD. XIAP could be a clinically relevant 
target, since its deficiency causes XLP-2 188, a rare PID clinically rather similar to XLP-1. If 
TMPA would indeed increase or stabilize XIAP function, it would represent a personalized 
compound to enhance the function of hypomorphic XIAP mutations. The TMPA mediated, 
Nur77-dependent downregulation of SAP could also be used therapeutically. SAP has been 
described to support T helper-cell dependent antibody formation in vivo191. As this includes 
SAP mediated support of autoantibody formation192,193, therapeutic reduction of SAP 
expression by TMPA related compounds could be used to lower auto-antibody production in 
autoimmune diseases. In addition, since SAP deficient T-cells show enhanced survival66, 
TMPA could be used during T-cell-dependent vaccinations (e.g. against HIV194) or adoptive 
T-cell transfer to treat tumors195. 
A very attractive use of the Nur77 binding small molecule compounds studied in this thesis 
would be to treat cancer by induction of Nur77-dependent apoptosis in cancer 
cells101,121,143,162,175 and at the same time to reduce RICD of cancer-specific T-cells. Whether 
such a dual-acting ‘super-compound’ fulfills its promises has to be tested in in vivo models of 
T-cell controlled tumors. A pharmacological reduction of T-cell RICD could also potentially 
improve treatment success in combination with checkpoint inhibitors during cancer 
therapy196,197,198. It is important to state that the in vivo application of Nur77 binding small 
molecule compounds may induce pleiotropic immunologic phenotypes. While early studies 
claimed, that mice lacking Nur77 did not have any immunological phenotype81,148,154, more 
recent studies demonstrated Nur77 to regulate other important immunological functions in 
both lymphoid and myeloid cells. The development of Ly6Clow monocytes occurs Nur77-
dependently and these cells orchestrate the monitoring and disposal of endothelial cells to 
control atherosclerosis199,200. In addition, caspase-independent cell death in macrophages 
was shown to depend on Nur77 201,202. More recent studies reported a role of Nur77 and 
Nor1 as suppressors of acute myeloid leukemia and myelodysplastic syndromes105,106. Also, 
the thymic development of regulatory T-cells is under the control of NR4A family proteins203–
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205. Still, TMPA has been applied in vivo and has not been described to cause toxicity96. Our 
plan is to titrate TMPA during acute and chronic murine infection with LCMV, a poorly-
cytopathic virus controlled by CD8+ T-cells206. A great advantage is, that the immune-control 
of LCMV is very well studied and tools to track virus-specific B- and T-cells exist207. In vivo 
use of TMPA, if used in human clinical trials, will require close monitoring of EBV replication, 
since it will be likely to induce a TMPA-dependent transient SAP deficiency177. Finally, the 
reported relevance of the NR4A receptors in chronic inflammatory diseases208 such as 
chronic arthritis209 and inflammation associated fibrosis210 point to the need for long term in 
vivo monitoring of the immunologic and other effects of Nur77 LBD binding compounds. 
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5 Appendix 
 
To this thesis, I attach my first authorship publication with the title “Detection of Sp110 by 
Flow Cytometry and Application to Screening Patients for Veno-occlusive Disease 
with Immunodeficiency.”, published in the Journal of Clinical Immunology in 2017. 
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